WO2019208803A1 - 微生物油及び微生物油の製造方法 - Google Patents
微生物油及び微生物油の製造方法 Download PDFInfo
- Publication number
- WO2019208803A1 WO2019208803A1 PCT/JP2019/018049 JP2019018049W WO2019208803A1 WO 2019208803 A1 WO2019208803 A1 WO 2019208803A1 JP 2019018049 W JP2019018049 W JP 2019018049W WO 2019208803 A1 WO2019208803 A1 WO 2019208803A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- content
- microbial oil
- epa
- less
- acid
- Prior art date
Links
- 230000000813 microbial effect Effects 0.000 title claims abstract description 221
- 238000004519 manufacturing process Methods 0.000 title claims description 30
- JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 claims abstract description 287
- 235000020673 eicosapentaenoic acid Nutrition 0.000 claims abstract description 278
- 229960005135 eicosapentaenoic acid Drugs 0.000 claims abstract description 278
- JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 claims abstract description 278
- MBMBGCFOFBJSGT-KUBAVDMBSA-N all-cis-docosa-4,7,10,13,16,19-hexaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 claims abstract description 173
- 235000014113 dietary fatty acids Nutrition 0.000 claims abstract description 152
- 229930195729 fatty acid Natural products 0.000 claims abstract description 152
- 239000000194 fatty acid Substances 0.000 claims abstract description 152
- 150000004665 fatty acids Chemical class 0.000 claims abstract description 147
- 235000020669 docosahexaenoic acid Nutrition 0.000 claims abstract description 90
- 229940090949 docosahexaenoic acid Drugs 0.000 claims abstract description 85
- 125000004432 carbon atom Chemical group C* 0.000 claims abstract description 44
- DVSZKTAMJJTWFG-SKCDLICFSA-N (2e,4e,6e,8e,10e,12e)-docosa-2,4,6,8,10,12-hexaenoic acid Chemical compound CCCCCCCCC\C=C\C=C\C=C\C=C\C=C\C=C\C(O)=O DVSZKTAMJJTWFG-SKCDLICFSA-N 0.000 claims abstract description 5
- GZJLLYHBALOKEX-UHFFFAOYSA-N 6-Ketone, O18-Me-Ussuriedine Natural products CC=CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O GZJLLYHBALOKEX-UHFFFAOYSA-N 0.000 claims abstract description 5
- KAUVQQXNCKESLC-UHFFFAOYSA-N docosahexaenoic acid (DHA) Natural products COC(=O)C(C)NOCC1=CC=CC=C1 KAUVQQXNCKESLC-UHFFFAOYSA-N 0.000 claims abstract description 5
- 239000003921 oil Substances 0.000 claims description 250
- 244000005700 microbiome Species 0.000 claims description 162
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 69
- 238000000034 method Methods 0.000 claims description 44
- 239000002609 medium Substances 0.000 claims description 37
- 238000012258 culturing Methods 0.000 claims description 34
- 235000021122 unsaturated fatty acids Nutrition 0.000 claims description 31
- 150000004670 unsaturated fatty acids Chemical class 0.000 claims description 30
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 28
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 claims description 28
- 239000008103 glucose Substances 0.000 claims description 28
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 27
- 239000002028 Biomass Substances 0.000 claims description 26
- 239000001963 growth medium Substances 0.000 claims description 26
- 150000004671 saturated fatty acids Chemical class 0.000 claims description 24
- 238000005273 aeration Methods 0.000 claims description 20
- YUFFSWGQGVEMMI-JLNKQSITSA-M (7Z,10Z,13Z,16Z,19Z)-docosapentaenoate Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCCCC([O-])=O YUFFSWGQGVEMMI-JLNKQSITSA-M 0.000 claims description 17
- IQLUYYHUNSSHIY-HZUMYPAESA-N eicosatetraenoic acid Chemical compound CCCCCCCCCCC\C=C\C=C\C=C\C=C\C(O)=O IQLUYYHUNSSHIY-HZUMYPAESA-N 0.000 claims description 16
- 235000021342 arachidonic acid Nutrition 0.000 claims description 14
- 229940114079 arachidonic acid Drugs 0.000 claims description 14
- 239000010779 crude oil Substances 0.000 claims description 10
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims description 10
- 238000001704 evaporation Methods 0.000 claims description 8
- 230000008020 evaporation Effects 0.000 claims description 8
- YUFFSWGQGVEMMI-JLNKQSITSA-N (7Z,10Z,13Z,16Z,19Z)-docosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCCCC(O)=O YUFFSWGQGVEMMI-JLNKQSITSA-N 0.000 claims description 7
- 241001466451 Stramenopiles Species 0.000 claims description 6
- 235000021294 Docosapentaenoic acid Nutrition 0.000 claims description 5
- 235000019198 oils Nutrition 0.000 description 228
- 239000000203 mixture Substances 0.000 description 39
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 23
- 238000000605 extraction Methods 0.000 description 23
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 22
- 230000008569 process Effects 0.000 description 22
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 19
- 229910052799 carbon Inorganic materials 0.000 description 19
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 description 17
- 238000000746 purification Methods 0.000 description 17
- -1 diglycerides Chemical class 0.000 description 15
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 15
- 239000003960 organic solvent Substances 0.000 description 14
- 235000003441 saturated fatty acids Nutrition 0.000 description 14
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 12
- 229920006395 saturated elastomer Polymers 0.000 description 12
- 239000007788 liquid Substances 0.000 description 11
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 10
- 210000004027 cell Anatomy 0.000 description 10
- 235000021588 free fatty acids Nutrition 0.000 description 10
- 235000020665 omega-6 fatty acid Nutrition 0.000 description 10
- 239000002904 solvent Substances 0.000 description 10
- 230000003042 antagnostic effect Effects 0.000 description 9
- 238000006460 hydrolysis reaction Methods 0.000 description 9
- 241000195493 Cryptophyta Species 0.000 description 7
- 241000233866 Fungi Species 0.000 description 7
- 239000003814 drug Substances 0.000 description 7
- 235000019387 fatty acid methyl ester Nutrition 0.000 description 7
- 230000007062 hydrolysis Effects 0.000 description 7
- 235000020660 omega-3 fatty acid Nutrition 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 230000002195 synergetic effect Effects 0.000 description 7
- HOBAELRKJCKHQD-UHFFFAOYSA-N (8Z,11Z,14Z)-8,11,14-eicosatrienoic acid Natural products CCCCCC=CCC=CCC=CCCCCCCC(O)=O HOBAELRKJCKHQD-UHFFFAOYSA-N 0.000 description 6
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 238000004440 column chromatography Methods 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 6
- 238000004821 distillation Methods 0.000 description 6
- 235000013305 food Nutrition 0.000 description 6
- 150000002632 lipids Chemical class 0.000 description 6
- 238000012545 processing Methods 0.000 description 6
- 150000001298 alcohols Chemical class 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 239000000470 constituent Substances 0.000 description 5
- HOBAELRKJCKHQD-QNEBEIHSSA-N dihomo-γ-linolenic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/CCCCCCC(O)=O HOBAELRKJCKHQD-QNEBEIHSSA-N 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 230000032050 esterification Effects 0.000 description 5
- 238000005886 esterification reaction Methods 0.000 description 5
- 230000001747 exhibiting effect Effects 0.000 description 5
- 229910052757 nitrogen Inorganic materials 0.000 description 5
- 150000003904 phospholipids Chemical class 0.000 description 5
- 238000007670 refining Methods 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 4
- 241000195620 Euglena Species 0.000 description 4
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 4
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 229930182558 Sterol Natural products 0.000 description 4
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 4
- 125000000217 alkyl group Chemical group 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 238000000354 decomposition reaction Methods 0.000 description 4
- 239000000284 extract Substances 0.000 description 4
- 238000007667 floating Methods 0.000 description 4
- 238000004817 gas chromatography Methods 0.000 description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 4
- 229920000642 polymer Polymers 0.000 description 4
- 230000001737 promoting effect Effects 0.000 description 4
- 238000011084 recovery Methods 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 235000003702 sterols Nutrition 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 239000013589 supplement Substances 0.000 description 4
- DCXXMTOCNZCJGO-UHFFFAOYSA-N tristearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 description 4
- 241000199913 Crypthecodinium Species 0.000 description 3
- 241000235575 Mortierella Species 0.000 description 3
- 241000199919 Phaeophyceae Species 0.000 description 3
- 125000005907 alkyl ester group Chemical group 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 239000002537 cosmetic Substances 0.000 description 3
- 230000001877 deodorizing effect Effects 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 239000003925 fat Substances 0.000 description 3
- 235000019197 fats Nutrition 0.000 description 3
- 239000007789 gas Substances 0.000 description 3
- 229910001629 magnesium chloride Inorganic materials 0.000 description 3
- 235000011147 magnesium chloride Nutrition 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000013535 sea water Substances 0.000 description 3
- 229920002379 silicone rubber Polymers 0.000 description 3
- 239000004945 silicone rubber Substances 0.000 description 3
- 235000002639 sodium chloride Nutrition 0.000 description 3
- 150000003432 sterols Chemical class 0.000 description 3
- 150000003626 triacylglycerols Chemical class 0.000 description 3
- FPRKGXIOSIUDSE-SYACGTDESA-N (2z,4z,6z,8z)-docosa-2,4,6,8-tetraenoic acid Chemical compound CCCCCCCCCCCCC\C=C/C=C\C=C/C=C\C(O)=O FPRKGXIOSIUDSE-SYACGTDESA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 241000195628 Chlorophyta Species 0.000 description 2
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 2
- 235000021298 Dihomo-γ-linolenic acid Nutrition 0.000 description 2
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 2
- 241000199914 Dinophyceae Species 0.000 description 2
- 235000021292 Docosatetraenoic acid Nutrition 0.000 description 2
- 244000068988 Glycine max Species 0.000 description 2
- 235000010469 Glycine max Nutrition 0.000 description 2
- 241001491670 Labyrinthula Species 0.000 description 2
- 239000004367 Lipase Substances 0.000 description 2
- 108090001060 Lipase Proteins 0.000 description 2
- 102000004882 Lipase Human genes 0.000 description 2
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- 241000233671 Schizochytrium Species 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 241000233675 Thraustochytrium Species 0.000 description 2
- 235000019270 ammonium chloride Nutrition 0.000 description 2
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 2
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 2
- 235000011130 ammonium sulphate Nutrition 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- 239000001110 calcium chloride Substances 0.000 description 2
- 229910001628 calcium chloride Inorganic materials 0.000 description 2
- 235000011148 calcium chloride Nutrition 0.000 description 2
- 229940041514 candida albicans extract Drugs 0.000 description 2
- 239000004202 carbamide Substances 0.000 description 2
- 239000003054 catalyst Substances 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000004927 clay Substances 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 235000008504 concentrate Nutrition 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 238000004042 decolorization Methods 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- UKMSUNONTOPOIO-UHFFFAOYSA-N docosanoic acid Chemical compound CCCCCCCCCCCCCCCCCCCCCC(O)=O UKMSUNONTOPOIO-UHFFFAOYSA-N 0.000 description 2
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 150000002170 ethers Chemical class 0.000 description 2
- 235000013312 flour Nutrition 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- 229930195733 hydrocarbon Natural products 0.000 description 2
- 150000002430 hydrocarbons Chemical class 0.000 description 2
- VKOBVWXKNCXXDE-UHFFFAOYSA-N icosanoic acid Chemical compound CCCCCCCCCCCCCCCCCCCC(O)=O VKOBVWXKNCXXDE-UHFFFAOYSA-N 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 235000019421 lipase Nutrition 0.000 description 2
- 238000009630 liquid culture Methods 0.000 description 2
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 2
- 235000019341 magnesium sulphate Nutrition 0.000 description 2
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 2
- 235000019796 monopotassium phosphate Nutrition 0.000 description 2
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 239000003208 petroleum Substances 0.000 description 2
- PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 description 2
- 239000001103 potassium chloride Substances 0.000 description 2
- 235000011164 potassium chloride Nutrition 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- VWDWKYIASSYTQR-UHFFFAOYSA-N sodium nitrate Chemical compound [Na+].[O-][N+]([O-])=O VWDWKYIASSYTQR-UHFFFAOYSA-N 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 238000001256 steam distillation Methods 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 150000003505 terpenes Chemical class 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000004809 thin layer chromatography Methods 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- 238000009423 ventilation Methods 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 239000012138 yeast extract Substances 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- XSXIVVZCUAHUJO-AVQMFFATSA-N (11e,14e)-icosa-11,14-dienoic acid Chemical compound CCCCC\C=C\C\C=C\CCCCCCCCCC(O)=O XSXIVVZCUAHUJO-AVQMFFATSA-N 0.000 description 1
- UNSRRHDPHVZAHH-YOILPLPUSA-N (5Z,8Z,11Z)-icosatrienoic acid Chemical compound CCCCCCCC\C=C/C\C=C/C\C=C/CCCC(O)=O UNSRRHDPHVZAHH-YOILPLPUSA-N 0.000 description 1
- LDVVTQMJQSCDMK-UHFFFAOYSA-N 1,3-dihydroxypropan-2-yl formate Chemical compound OCC(CO)OC=O LDVVTQMJQSCDMK-UHFFFAOYSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- PAWQVTBBRAZDMG-UHFFFAOYSA-N 2-(3-bromo-2-fluorophenyl)acetic acid Chemical compound OC(=O)CC1=CC=CC(Br)=C1F PAWQVTBBRAZDMG-UHFFFAOYSA-N 0.000 description 1
- TWJNQYPJQDRXPH-UHFFFAOYSA-N 2-cyanobenzohydrazide Chemical compound NNC(=O)C1=CC=CC=C1C#N TWJNQYPJQDRXPH-UHFFFAOYSA-N 0.000 description 1
- UNSRRHDPHVZAHH-UHFFFAOYSA-N 6beta,11alpha-Dihydroxy-3alpha,5alpha-cyclopregnan-20-on Natural products CCCCCCCCC=CCC=CCC=CCCCC(O)=O UNSRRHDPHVZAHH-UHFFFAOYSA-N 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 1
- 239000005695 Ammonium acetate Substances 0.000 description 1
- 241000224482 Apicomplexa Species 0.000 description 1
- 241000003610 Aplanochytrium Species 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 241001306132 Aurantiochytrium Species 0.000 description 1
- 241001467606 Bacillariophyceae Species 0.000 description 1
- 241000206761 Bacillariophyta Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 235000021357 Behenic acid Nutrition 0.000 description 1
- 241001466491 Bicosoecida Species 0.000 description 1
- 241000726108 Blastocystis Species 0.000 description 1
- 241001536324 Botryococcus Species 0.000 description 1
- 241000534674 Chrysomerophyceae Species 0.000 description 1
- 241000206751 Chrysophyceae Species 0.000 description 1
- 241000223782 Ciliophora Species 0.000 description 1
- 241001527609 Cryptococcus Species 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- 241000305506 Desmodesmus Species 0.000 description 1
- 241001529919 Dictyochophyceae Species 0.000 description 1
- 235000021297 Eicosadienoic acid Nutrition 0.000 description 1
- KIWBPDUYBMNFTB-UHFFFAOYSA-N Ethyl hydrogen sulfate Chemical compound CCOS(O)(=O)=O KIWBPDUYBMNFTB-UHFFFAOYSA-N 0.000 description 1
- 241000195623 Euglenida Species 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 230000005526 G1 to G0 transition Effects 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 241000144604 Hyphochytriomycetes Species 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 241000003482 Japonochytrium Species 0.000 description 1
- 239000005639 Lauric acid Substances 0.000 description 1
- 235000021353 Lignoceric acid Nutrition 0.000 description 1
- CQXMAMUUWHYSIY-UHFFFAOYSA-N Lignoceric acid Natural products CCCCCCCCCCCCCCCCCCCCCCCC(=O)OCCC1=CC=C(O)C=C1 CQXMAMUUWHYSIY-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 208000001145 Metabolic Syndrome Diseases 0.000 description 1
- 241000907999 Mortierella alpina Species 0.000 description 1
- 241001219224 Mortierella elongata Species 0.000 description 1
- 241000048020 Mortierella exigua Species 0.000 description 1
- 241000133355 Mortierella hygrophila Species 0.000 description 1
- 235000021360 Myristic acid Nutrition 0.000 description 1
- TUNFSRHWOTWDNC-UHFFFAOYSA-N Myristic acid Natural products CCCCCCCCCCCCCC(O)=O TUNFSRHWOTWDNC-UHFFFAOYSA-N 0.000 description 1
- 241001306135 Oblongichytrium Species 0.000 description 1
- 241000360410 Opalinidae Species 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 241001494902 Pelagophyceae Species 0.000 description 1
- 239000001888 Peptone Substances 0.000 description 1
- 108010080698 Peptones Proteins 0.000 description 1
- 241000233614 Phytophthora Species 0.000 description 1
- 241000235648 Pichia Species 0.000 description 1
- 241000119236 Rhizaria Species 0.000 description 1
- 241000235070 Saccharomyces Species 0.000 description 1
- 241000195663 Scenedesmus Species 0.000 description 1
- 241000598397 Schizochytrium sp. Species 0.000 description 1
- 241000242583 Scyphozoa Species 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 241001467333 Thraustochytriaceae Species 0.000 description 1
- 241000144181 Thraustochytrium aureum Species 0.000 description 1
- 241000817756 Thraustochytrium roseum Species 0.000 description 1
- 241001298230 Thraustochytrium sp. Species 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- 241000223230 Trichosporon Species 0.000 description 1
- 241001491678 Ulkenia Species 0.000 description 1
- 241000206764 Xanthophyceae Species 0.000 description 1
- 241000235013 Yarrowia Species 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 238000005903 acid hydrolysis reaction Methods 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 150000001338 aliphatic hydrocarbons Chemical class 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- OBETXYAYXDNJHR-UHFFFAOYSA-N alpha-ethylcaproic acid Natural products CCCCC(CC)C(O)=O OBETXYAYXDNJHR-UHFFFAOYSA-N 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 235000019257 ammonium acetate Nutrition 0.000 description 1
- 229940043376 ammonium acetate Drugs 0.000 description 1
- 229940044197 ammonium sulfate Drugs 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
- 150000004945 aromatic hydrocarbons Chemical class 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- OGBUMNBNEWYMNJ-UHFFFAOYSA-N batilol Chemical class CCCCCCCCCCCCCCCCCCOCC(O)CO OGBUMNBNEWYMNJ-UHFFFAOYSA-N 0.000 description 1
- 229940116226 behenic acid Drugs 0.000 description 1
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 1
- 239000000920 calcium hydroxide Substances 0.000 description 1
- 229910001861 calcium hydroxide Inorganic materials 0.000 description 1
- 235000011116 calcium hydroxide Nutrition 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 235000013877 carbamide Nutrition 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 150000001721 carbon Chemical group 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 235000021466 carotenoid Nutrition 0.000 description 1
- 150000001747 carotenoids Chemical class 0.000 description 1
- 239000012159 carrier gas Substances 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 229940106189 ceramide Drugs 0.000 description 1
- 150000001783 ceramides Chemical class 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- RCTFHBWTYQOVGJ-UHFFFAOYSA-N chloroform;dichloromethane Chemical compound ClCCl.ClC(Cl)Cl RCTFHBWTYQOVGJ-UHFFFAOYSA-N 0.000 description 1
- SIHHLZPXQLFPMC-UHFFFAOYSA-N chloroform;methanol;hydrate Chemical compound O.OC.ClC(Cl)Cl SIHHLZPXQLFPMC-UHFFFAOYSA-N 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 235000017471 coenzyme Q10 Nutrition 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 238000004185 countercurrent chromatography Methods 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000004332 deodorization Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 150000001982 diacylglycerols Chemical class 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- PXEDJBXQKAGXNJ-QTNFYWBSSA-L disodium L-glutamate Chemical compound [Na+].[Na+].[O-]C(=O)[C@@H](N)CCC([O-])=O PXEDJBXQKAGXNJ-QTNFYWBSSA-L 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 239000003221 ear drop Substances 0.000 description 1
- 229940047652 ear drops Drugs 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- FARYTWBWLZAXNK-WAYWQWQTSA-N ethyl (z)-3-(methylamino)but-2-enoate Chemical compound CCOC(=O)\C=C(\C)NC FARYTWBWLZAXNK-WAYWQWQTSA-N 0.000 description 1
- 125000004494 ethyl ester group Chemical group 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 235000021323 fish oil Nutrition 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 125000005908 glyceryl ester group Chemical group 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- JEGUKCSWCFPDGT-UHFFFAOYSA-N h2o hydrate Chemical compound O.O JEGUKCSWCFPDGT-UHFFFAOYSA-N 0.000 description 1
- 239000001307 helium Substances 0.000 description 1
- 229910052734 helium Inorganic materials 0.000 description 1
- SWQJXJOGLNCZEY-UHFFFAOYSA-N helium atom Chemical compound [He] SWQJXJOGLNCZEY-UHFFFAOYSA-N 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- FUKUFMFMCZIRNT-UHFFFAOYSA-N hydron;methanol;chloride Chemical compound Cl.OC FUKUFMFMCZIRNT-UHFFFAOYSA-N 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 150000004702 methyl esters Chemical class 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 235000013379 molasses Nutrition 0.000 description 1
- 150000002759 monoacylglycerols Chemical class 0.000 description 1
- 235000013923 monosodium glutamate Nutrition 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- 239000007923 nasal drop Substances 0.000 description 1
- 229940100662 nasal drops Drugs 0.000 description 1
- 150000002825 nitriles Chemical class 0.000 description 1
- 239000012454 non-polar solvent Substances 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 238000005453 pelletization Methods 0.000 description 1
- 235000019319 peptone Nutrition 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 229940073490 sodium glutamate Drugs 0.000 description 1
- 239000004317 sodium nitrate Substances 0.000 description 1
- 235000010344 sodium nitrate Nutrition 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 150000003408 sphingolipids Chemical class 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 235000019149 tocopherols Nutrition 0.000 description 1
- 238000011426 transformation method Methods 0.000 description 1
- 150000003669 ubiquinones Chemical class 0.000 description 1
- 229940045136 urea Drugs 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 150000003735 xanthophylls Chemical class 0.000 description 1
- 235000008210 xanthophylls Nutrition 0.000 description 1
- QUEDXNHFTDJVIY-UHFFFAOYSA-N γ-tocopherol Chemical class OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1 QUEDXNHFTDJVIY-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P7/00—Preparation of oxygen-containing organic compounds
- C12P7/64—Fats; Fatty oils; Ester-type waxes; Higher fatty acids, i.e. having at least seven carbon atoms in an unbroken chain bound to a carboxyl group; Oxidised oils or fats
- C12P7/6436—Fatty acid esters
- C12P7/6445—Glycerides
- C12P7/6472—Glycerides containing polyunsaturated fatty acid [PUFA] residues, i.e. having two or more double bonds in their backbone
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23D—EDIBLE OILS OR FATS, e.g. MARGARINES, SHORTENINGS, COOKING OILS
- A23D9/00—Other edible oils or fats, e.g. shortenings, cooking oils
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
-
- C—CHEMISTRY; METALLURGY
- C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
- C11B—PRODUCING, e.g. BY PRESSING RAW MATERIALS OR BY EXTRACTION FROM WASTE MATERIALS, REFINING OR PRESERVING FATS, FATTY SUBSTANCES, e.g. LANOLIN, FATTY OILS OR WAXES; ESSENTIAL OILS; PERFUMES
- C11B1/00—Production of fats or fatty oils from raw materials
- C11B1/10—Production of fats or fatty oils from raw materials by extracting
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/12—Unicellular algae; Culture media therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P7/00—Preparation of oxygen-containing organic compounds
- C12P7/64—Fats; Fatty oils; Ester-type waxes; Higher fatty acids, i.e. having at least seven carbon atoms in an unbroken chain bound to a carboxyl group; Oxidised oils or fats
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
- C12N2500/35—Polyols, e.g. glycerin, inositol
Definitions
- This disclosure relates to a microbial oil and a method for producing a microbial oil.
- Eicosapentaenoic acid hereinafter abbreviated as EPA
- DHA docosahexaenoic acid
- n-3 polyunsaturated fatty acids have various physiological functions, and can be used for pharmaceuticals, health It is used as food and food material. Beverages to which oil containing EPA is added are also approved as foods for specified health use. The demand for n-3 polyunsaturated fatty acids as a supplement is very high both at home and abroad. Accordingly, it is required to produce polyunsaturated fatty acids with high purity and in large quantities.
- Patent Document 1 discloses a stramenopile transformation method capable of producing a microbial oil having an increased unsaturated fatty acid content by genetic recombination technology.
- Patent Document 2 discloses a method for producing an unsaturated fatty acid-enriched oil, comprising a step of subjecting an oil or fat containing an unsaturated fatty acid to a hydrolysis reaction with lipase, and a step of separating a glyceride fraction in which the unsaturated fatty acid is concentrated.
- the present disclosure includes: [1] A group comprising eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), wherein the content of eicosapentaenoic acid is 38% by area or more based on the total fatty acids, and is composed of the following (a) to (c) A microbial oil having at least one fatty acid ratio selected from: (A) the ratio of the EPA content to the DHA content of 1.7 or more, (B) The ratio of the content of 18 fatty acids to the content of 20 or less fatty acids of 0.3 or less, (C) The ratio of the content of fatty acids having 18 carbons to the content of fatty acids having 22 or less carbons of 1.5 or less.
- EPA eicosapentaenoic acid
- DHA docosahexaenoic acid
- n-3DPA docosapentaenoic acid
- ETA eicosatetraenoic acid
- [17] A microbial oil obtained by the production method according to any one of [13] to [16].
- [18] Preparing a microorganism that does not grow in a medium containing glucose or that can produce a microbial oil containing more docosahexaenoic acid than eicosapentaenoic acid, and preparing the prepared microorganism at 30 mL / min to 1500 mL / min
- a microorganism comprising culturing in a culture medium containing glycerol under an aeration environment of less than or equal to min, and obtaining microbial oil containing more eicosapentaenoic acid than docosahexaenoic acid from biomass obtained by the culture
- a method for controlling the fatty acid content of oil Preparing a microorganism that does not grow in a medium containing glucose or that can produce a microbial oil containing more docosahexaenoic acid than eico
- a microbial oil containing EPA at a high concentration and capable of effectively exhibiting the function of EPA, and a method for producing the same.
- the microbial oil according to the present disclosure contains eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), and the content of eicosapentaenoic acid is 38 area% or more based on the total fatty acids, and the following (a) to (c) A microbial oil having a ratio of at least one fatty acid selected from the group consisting of: (A) the ratio of the EPA content to the DHA content of 1.7 or more, (B) The ratio of the content of 18 fatty acids to the content of 20 or less fatty acids of 0.3 or less, (C) The ratio of the content of fatty acids having 18 carbons to the content of fatty acids having 22 or less carbons of 1.5 or less.
- EPA eicosapentaenoic acid
- DHA docosahexaenoic acid
- the microbial oil according to the present disclosure has EPA in an amount of 38% by area or more based on the total fatty acids and at least one of the fatty acid ratios (a) to (c) described above. However, it can be effectively demonstrated. To explain this further, when the microbial oil of the present disclosure has a ratio of the content of EPA to the content of DHA equal to or higher than a certain level, the desired function of EPA can be effectively exhibited. Moreover, since DHA is included with EPA, the synergistic effect of DHA and EPA can also be expected.
- a saturated or unsaturated fatty acid having 18 carbon atoms is known as a precursor of a polyunsaturated fatty acid having 20 or more carbon atoms.
- the content of such a saturated or unsaturated fatty acid having 18 carbon atoms is a ratio below a certain level with respect to the content of 20 fatty acids or 22 fatty acids.
- EPA and DHA can be efficiently used to obtain EPA and DHA, and EPA and DHA can be contained in microbial oil with high purity.
- the content ratio of fatty acids having 18 carbon atoms is suppressed within a predetermined range, or the content ratio of DHA that can be produced together is within a predetermined range. I can expect.
- the microbial oil according to the present disclosure including EPA and DHA, the EPA content rate is 38 area% or more based on the total fatty acids, and having predetermined requirements is referred to as “EPA-rich microbial oil”. There is a case.
- the method for producing a microbial oil according to the present disclosure includes preparing a microorganism having the ability to produce both eicosapentaenoic acid and docosahexaenoic acid, and subjecting the prepared microorganism to a glycerol in an aeration environment of 30 mL / min to 1500 mL / min.
- a microbial oil containing a high content of EPA according to the present disclosure from the biomass obtained after culturing.
- the method for producing a microbial oil according to the present disclosure includes culturing a microorganism capable of producing EPA and DHA in a medium containing glycerol under a predetermined aeration environment.
- the culture medium containing glycerol used in the method for producing a microbial oil according to the present disclosure may contain glucose at a glucose concentration at which the microorganisms grow and the content of eicosapentaenoic acid in the microbial oil is higher than the content of docosahexaenoic acid. Good.
- the term “process” is not limited to an independent process, and is included in the term if the intended purpose of the process is achieved even when it cannot be clearly distinguished from other processes. .
- a numerical range indicated by using “to” indicates a range including numerical values described before and after the numerical value as a minimum value and a maximum value, respectively.
- the content of each component in the mixture is the total content of the plurality of substances present in the mixture unless there is a specific indication when there are a plurality of substances corresponding to each component in the mixture. means.
- the term “below” or “less than” in terms of percentage includes 0%, ie, “does not contain” unless otherwise specified, or includes a value not detectable by current means. Means range.
- biomass refers to a collection or mass of microorganisms or cells at a given point in time in a given region or ecosystem.
- This region or ecosystem may be a naturally occurring environment (eg, a body of water) or a synthetic environment (eg, a fermentor or bioreactor (eg, open or closed)).
- microbial oil refers to a mixture of organic substances obtained from microbial biomass and insoluble in water at room temperature and normal pressure, that is, at 25 ° C. and 1 atmosphere.
- Microbial oils contain oily components such as saturated or unsaturated fatty acids, phospholipids, sterols, glycerol, ceramides, sphingolipids, terpenoids, flavonoids, tocopherols, and saturated or unsaturated fatty acids are constituent fatty acids in other oily components It may exist as As used herein, “oil” means a composition containing these lipids and oily components.
- fatty acid includes not only free saturated or unsaturated fatty acids themselves, but also free saturated or unsaturated fatty acids, saturated or unsaturated fatty acid alkyl esters, triglycerides, diglycerides, monoglycerides, phospholipids, steryl esters and the like. Fatty acids as constituent units are also included and can be rephrased as constituent fatty acids.
- the form of a compound containing a fatty acid may be omitted. Examples of the form of the compound containing a fatty acid include a free fatty acid form, a fatty acid alkyl ester form, a glyceryl ester form, a phospholipid form, and a steryl ester form.
- the compound containing the same fatty acid may be contained in a single form in the oil, or may be contained as a mixture of two or more forms.
- the reaction efficiency of fatty acid hydrolysis or alcohol decomposition is high, and after hydrolysis or alcohol decomposition, a composition containing fatty acids mainly in the form of free fatty acids or their lower alcohol esters is obtained. .
- the fatty acid after the processing step may be expressed by omitting that it is a composition and that the fatty acid is a fatty acid in the form of a free fatty acid or a lower alcohol ester.
- it does not completely exclude the inclusion of fatty acids in a form other than the free fatty acid form or the lower alcohol ester form.
- a numerical expression that simply represents the number of carbon atoms, the number of double bonds, and the location of the double bond using numerals and alphabets may be used.
- a saturated fatty acid having 20 carbon atoms is expressed as “C20: 0”
- a triunsaturated fatty acid having 20 carbon atoms and three double bonds in the carbon chain is expressed as “C20: 3”.
- eicosapentaenoic acid can be represented as “C20: 5, n-3”, docosahexaenoic acid as “C22: 6, n-3”, and the like.
- N- indicates the position of the first double bond counted from the methyl terminus of the fatty acid.
- n-6 the position of the double bond is the sixth counted from the methyl terminus of the fatty acid.
- N-3 indicates that the position of the double bond is third from the methyl terminal of the fatty acid.
- fatty acid represented according to this method can be easily identified by those skilled in the art.
- the expression by a combination of the number of carbon atoms and the term “fatty acid”, such as “fatty acid having 20 carbon atoms”, is a saturated fatty acid having the carbon number and a monovalent or higher saturated fatty acid having the carbon number.
- a C20 fatty acid includes a C20 saturated fatty acid, a C20 monovalent unsaturated fatty acid, and a C20 divalent or higher unsaturated fatty acid.
- polyunsaturated fatty acids having 20 or more carbon atoms may be referred to as “PUFA” unless otherwise specified.
- the polyunsaturated fatty acids having 20 or more carbon atoms in PUFA include divalent or higher, preferably trivalent or higher unsaturated fatty acids.
- the carbon number of the polyunsaturated fatty acid means the carbon number of the constituent fatty acid.
- Examples of the polyunsaturated fatty acid having 20 or more carbon atoms include polyunsaturated fatty acids having 20 to 22 carbon atoms, specifically, eicosadienoic acid (C20: 2, n-6, EDA).
- Dihomo- ⁇ -linolenic acid (C20: 3, n-6, DGLA), mead acid (C20: 3, n-9, MA), eicosatetraenoic acid (C20: 4, n-3, ETA) Arachidonic acid (C20: 4, n-6, ARA), eicosapentaenoic acid (C20: 5, n-3, EPA), docosatetraenoic acid (C22: 4, n-6, DTA), docosapentaenoic acid (C22: 5, n-3, DPA), docosapentaenoic acid (C22: 5, n-6, DPA) and docosahexaenoic acid (C22: 6, n-3, DHA).
- an n-3 PUFA may be particularly referred to as “n-3 PUFA” and an n-6 PUFA may be referred to as “n-6 PUFA”.
- the fatty acid content relative to the total weight of fatty acids in the oil in this specification is determined based on the fatty acid composition.
- the fatty acid composition can be determined according to a conventional method. Specifically, the oil to be measured is esterified using a lower alcohol and a catalyst to obtain a fatty acid lower alcohol ester. Subsequently, the obtained fatty acid lower alcohol ester is analyzed using gas chromatography. The peak corresponding to each fatty acid is identified in the obtained gas chromatography chart, and the peak area of each fatty acid is obtained using the Agilent ChemStation integration algorithm (revision C.01.03 [37], Agilent Technologies).
- the peak area is the total peak area of each component of the chart analyzed by gas chromatography, thin layer chromatography / flame ionization detector (TLC / FID) etc. It is a ratio (area%) to the area and indicates the content ratio of the peak component.
- the value by area% obtained by the measurement method described above can be used interchangeably as being the same as the value by weight% of each fatty acid in the sample.
- JOCS Japan Oil Chemists' Society
- Fatty Acid Composition Fatty Acid Composition
- FID Ascension See Warm Gas Chromatograph Method
- the EPA-rich microbial oil includes eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), and the content of eicosapentaenoic acid is 38 area% or more based on the total fatty acids, Microbial oil having a ratio of at least one fatty acid selected from the group consisting of the following (a) to (c): (A) the ratio of the EPA content to the DHA content of 1.7 or more, (B) The ratio of the content of 18 fatty acids to the content of 20 or less fatty acids of 0.3 or less, (C) The ratio of the content of fatty acids having 18 carbons to the content of fatty acids having 22 or less carbons of 1.5 or less.
- the content of EPA in the EPA-rich microbial oil is 38 areas or more from the viewpoint of EPA functionality, purification efficiency, etc., 38.5 area% or more, 39 area% or more, 39.5 area% or more, 40 Area% or more, 40.5 area% or more, 41 area%, 41.5 area% or more, 42 area% or more, 42.5 area% or more, 43 area% or more, 43.5 area% or more, 44 area%, 44.5 area% or more, 45 area% or more, 45.5 area% or more, 46 area%, 46.5 area% or more, 47 area% or more, 47.5 area% or more, 48 area% or more, 48.5 Area% or more, 49 area%, 49.5 area% or more, or 50 area% or more.
- the upper limit of EPA in EPA high content microbial oil For example, 99.5 area% or less, 99.3% area% or less, 99 area% or less, 98.5 area% or less, 98 area% or less, Or it can be 97 area% or less.
- the range of the EPA content can be any combination of these upper and lower limits.
- the EPA-rich microbial oil contains DHA together with EPA.
- the DHA content is higher than the EPA content. Preferably it is low.
- the DHA content in the EPA-rich microbial oil is 0.5 area or more, 0.7 area% or more, from the viewpoints of EPA function, DHA function, and synergistic effect of EPA and DHA. Area% or more, 1.5 area% or more, 2 area% or more, or 3 area% or more can be set.
- the upper limit of DHA in EPA-rich microbial oil is 25 area% or less, 22 area% or less, 20 area% or less, 18 area% or less, 15 area% or less, 13 area% or less in terms of EPA purification efficiency. 12 area% or less, 11.5 area% or less, or 11 area% or less.
- the DHA content range can be any combination of these upper and lower limits, for example, 0.5 area% or more and 25 area% or less, or 1.5 area% or more. It can be made into 15 area% or less.
- EPA-rich microbial oil may or may not contain other saturated or unsaturated fatty acids other than EPA and DHA.
- the content of other saturated or unsaturated fatty acids other than EPA and DHA in the EPA-rich microbial oil is from the viewpoint of the function, characteristics, etc. of each fatty acid, or from the viewpoint of exhibiting the functionality of the EPA-rich microbial oil, respectively.
- the content may be 0 area% or may be more than 0 area%.
- Examples of other saturated or unsaturated fatty acids other than EPA and DHA include saturated fatty acids that do not limit the number of carbon atoms, monovalent unsaturated fatty acids having 18 carbon atoms, divalent unsaturated fatty acids having 18 carbon atoms, and carbon numbers other than EPA. Examples thereof include 20 unsaturated fatty acids, 21 unsaturated fatty acids, 22 unsaturated fatty acids other than DHA, and other unsaturated fatty acids.
- the EPA-rich microbial oil according to an embodiment of the present disclosure has a viewpoint of effectively exerting the function of EPA, a viewpoint of purification efficiency of a high-purity EPA-containing composition, and a viewpoint of obtaining at least one or more of advantages described below. And at least one selected from the group consisting of the following fatty acid contents and ratios.
- the ratio of the EPA content to the DHA content is 1.7 or more, 1.8 or more from the viewpoint of EPA functional performance, purification efficiency, etc. 1.9 or more, 2.0 or more, 2.2 or more, 2.5 or more, 2.7 or more, 3.0 or more, 3.2 or more, 3.5 or more, 3.7 or more, 4.0 or more It may be 4.2 or more, 4.4 or more, 4.5 or more, 4.7 or more, or 5.0 or more.
- limiting in particular about the upper limit of EPA / DHA ratio For example, it can be 10.0 or less, or 8.0 or less.
- the range of the EPA / DHA ratio can be any combination of these upper and lower limits, for example, 1.7 or more and 10.0 or less, or 3.0 or more and 8.0 or less. It can be.
- the content of the fatty acid having 18 carbon atoms is 0.3 or less with respect to the content of the fatty acid having 20 carbon atoms, from the viewpoint of the purity of EPA, the function of EPA, and the like. .1 or less, 0.05 or less, 0.03 or less, or 0.02 or less.
- the content of the fatty acid having 18 carbon atoms is 1 with respect to the content of the fatty acid having 22 carbon atoms from the viewpoint of effectively exhibiting the synergistic effect of DHA on EPA. 0.5 or less, 1.0 or less, 0.5 or less, 0.1 or less, 0.08 or less, or 0.05 or less.
- fatty acids having 18 carbon atoms may not be contained, and therefore the lower limit of the content of fatty acids having 18 carbon atoms may be 0 area%.
- the EPA-rich microorganism has advantages such as, for example, the purity of EPA, the performance of EPA, and the purification efficiency by having at least one fatty acid ratio selected from the group consisting of (a) to (c) above. be able to.
- the EPA-rich microorganism may have at least one fatty acid content or ratio selected from the group consisting of (d) to (n) below.
- saturated fatty acids (hereinafter simply referred to as saturated fatty acids) that do not limit the number of carbon atoms is 40 area% or less, 30 area% or less, 25 area% or less, 20 area% or less, 19 area with respect to all fatty acids. % Or less, 18 area% or less, 17 area% or less, or 15 area% or less.
- a EPA-rich microbial oil having a saturated fatty acid content in this range can have advantages such as better stability at low temperatures and better handling properties.
- D ′ In the EPA-rich microbial oil, the ratio of the content of saturated fatty acid to EPA is 1.5 or less, 1.1 or less, from the viewpoint of excellent handleability at low temperatures where the stability of PUFA is good.
- saturated fatty acids that can be contained in the EPA-rich microbial oil include saturated fatty acids having 12 or more carbon atoms.
- saturated fatty acids having 12 or more carbon atoms include lauric acid (C12: 0), myristic acid (C14: 0), palmitic acid (C16: 0), stearic acid (C18: 0), and arachidic acid (C20: 0). , Behenic acid (C22: 0), and lignoceric acid (C24: 0).
- the content of arachidonic acid (C20: 4, n-6, ARA) in particular is 10.0 area% or less and 5.0 areas with respect to the total fatty acids. % Or less, 3.0 area% or less, 2.5 area% or less, or 2.0 area% or less. If the content of arachidonic acid in the EPA-rich microbial oil is within this range, the EPA-rich microbial oil can achieve an effect that is more than the antagonistic action of n-6 PUFA.
- the ratio of the content of ARA to EPA is 5.0 or less, 1.0 or less, 0.5 or less, 0.1 or less from the viewpoint of antagonistic action by n-6 PUFA. 0.08 or less, 0.05 or less, or 0.04 or less.
- the content of eicosatetraenoic acid (C20: 4, n-3, ETA) in particular is 0.1 area% or more based on the total fatty acids, 0 It may be 0.5 area% or more, or 1.0 area% or more.
- Eicosatetraenoic acid is contained in the EPA-rich microbial oil at this content to obtain the function of EPA, the function of DHA, the function of ETA, and the synergistic effect of EPA, DHA and ETA. be able to.
- the upper limit of the ETA content is 10.0 area% or less, 5.0 area% or less, 3.0 area% or less, 2.0 area% or less, or 1.8 area in relation to the EPA content. % Or less.
- the range of the ETA content in EPA-rich microorganisms can be any combination of these upper and lower limits, for example, 0.1 area% or more and 10.0 area% or less, or 0.5 area. % Or more and 5.0 area% or less.
- the ratio of the content of ETA to EPA is 1.6 or less, 1.0 or less, or 0.05 or less from the viewpoints of EPA functionality, purification efficiency, and the like. can do.
- the lower limit of the ETA / EPA ratio is not particularly limited, and can be, for example, 0.001 or more and 0.005 or more.
- the range of the ETA / EPA ratio can be any combination of these upper and lower limits, for example 0.001 or more and 1.6 or less, or 0.001 or more and 1.0 or less. It can be.
- the EPA-rich microbial oil can contain n-3 unsaturated fatty acids having 22 or more carbon atoms, preferably trivalent or more, in addition to DHA.
- n-3C22PUFA a divalent or higher-valent n-3 unsaturated fatty acid having 22 or more carbon atoms
- Examples of n-3C22PUFA include docosapentaenoic acid (C22: 5, n-3, n-3DPA) and DHA.
- the total content of n-3C22PUFA in the EPA-rich microbial oil is determined from the viewpoints of EPA function, DHA function, n-3C22 PUFA function, and synergistic effects of EPA, DHA and n-3 PUFA.
- 0.3 area% or more 0.5 area% or more, 1.0 area% or more, 5.0 area% or more, 8.0 area% or more, 10 area% or more, 15 area% or more, or 19 of all fatty acids It can be made to be area% or more, and can be 35 area% or less, 30 area% or less, 25 area% or less, 23 area% or less, or 20 area% or less.
- the range of the total content of PUFA in the EPA-rich microorganism can be any combination of these upper and lower limits, for example, 0.5 area% or more and 35 area% or less, or 10 area% or more and 25 It can be made into area% or less.
- the ratio of the content of n-3C22PUFA to EPA is the function of EPA, the function of DHA, the function of n-3C22PUFA, And from the viewpoint of the synergistic effect of EPA, DHA and n-3 PUFA, it can be 3.0 or less, 2.0 or less, 1.0 or less, or 0.6 or less.
- the lower limit value of the n-3C22PUFA / EPA ratio can be, for example, 0.01 or more.
- n-3DPA The content of n-3DPA in the EPA-rich microbial oil is 0.3% area% or more, 1.0 area% or more, 3.0 area% or more, 5.0 area% or more based on the total fatty acids. Or 8.0 area% or more.
- n-3DPA When n-3DPA is contained in EPA-rich microbial oil at this content, EPA functions, DHA functions, n-3DPA functions, and synergistic effects of EPA, DHA and n-3DPA Can be obtained.
- the upper limit of the content of n-3DPA can be 20.0 area% or less, 15.0 area%, or 12.0 area% or less in relation to the EPA content.
- the range of the content of n-3DPA can be any combination of these upper and lower limits, for example, 0.3 area% or more and 20.0 area% or less, or 8. It can be 0 area% or more and 15.0 area% or less.
- H ′ In the EPA-rich microbial oil, the ratio of the content of n-3DPA to EPA is 8.0 or less, 6.0 or less, or 5.0, from the viewpoints of EPA functionality, purification efficiency, and the like. It can be as follows.
- the content of n-6DPA in the EPA-rich microbial oil is 2.0 area% or less, 1.0 area% or less, 0.5 area% or less, or 0.1 area% or less based on the total fatty acids. It can be. If the content of n-6DPA in the EPA-rich microbial oil is within this range, the EPA-rich microbial oil can obtain an effect that is more than the antagonistic action of n-6 PUFA.
- the ratio of the content of n-6PDA to EPA is 1.0 or less, 0.1 or less, or 0.01 or less from the viewpoint of antagonistic action by n-6PUFA. be able to.
- n-6DPA In the EPA-rich microbial oil, from the viewpoint of the antagonistic action by n-6 PUFA, the content of n-6DPA is 2.0 or less, 1.0 or less, 0.1 or less relative to the content of n-3DPA. Or less or 0.01 or less.
- the EPA-rich microbial oil may contain a monovalent or higher unsaturated fatty acid having 18 carbon atoms.
- the total content of unsaturated fatty acids having 18 carbon atoms in the EPA high-content microbial oil is 2.0 area% or less, 1.0 area% with respect to the total fatty acids from the viewpoints of EPA functionality, improved purification efficiency, and the like. Hereinafter, it can be 0.5 area% or less, or 0.2 area% or less.
- K ′ In the EPA-rich microbial oil, the ratio of the total content of unsaturated fatty acids having 18 carbon atoms with respect to EPA is 2.0 or less, 1.0 from the viewpoints of EPA functional performance, purification efficiency improvement, and the like. Hereinafter, it can be 0.1 or less, 0.05 or less, 0.02 or less, or 0.01 or less.
- the content of fatty acids having 21 carbon atoms may be 2.0 area% or less, 1.5 area% or less, or 1.0 area% or less with respect to the total fatty acids. it can.
- the EPA-rich microbial oil having a content of 21 fatty acids having the above-mentioned range can have advantages such as better stability at low temperatures and better handling properties.
- the ratio of the content of fatty acids having 21 carbon atoms to EPA is 1.0 or less, 0.1 or less, or 0. 02 or less.
- the content of dihomo- ⁇ -linolenic acid (C20: 3, n-6, DGLA) in particular is 5.0 area% or less based on the total fatty acids, It can be 1.0 area% or less, 0.5 area% or less, or 0.1 area% or less. If the content of DGLA in the EPA-rich microbial oil is within this range, the EPA-rich microbial oil can obtain an effect that is more than the antagonistic action of n-6 PUFA.
- the ratio of the content of DGLA fatty acid to EPA is 1.0 or less, 0.1 or less, 0.05 or less, or 0 .01 or less.
- the content of docosatetraenoic acid (C22: 4, n-6, DTA), in particular, is 2.0 area% or less with respect to the total fatty acids. It can be 5 area% or less, or 1.0 area% or less. If the DTA content in the EPA-rich microbial oil is within this range, the EPA-rich microbial oil can achieve an effect that is greater than the antagonistic action of n-6 PUFA.
- the ratio of the fatty acid content of DTA to EPA is 1.0 or less, 0.1 or less, 0.05 or less, or 0 0.02 or less.
- the EPA-rich microbial oil can have at least one of the fatty acid contents or ratios (a) to (n ′), contains EPA at a high concentration, and effectively exhibits the function of EPA. , (A) to (n ′) at least one fatty acid content or ratio selected from the group consisting of.
- the EPA-rich microbial oil may be a crude oil or a refined oil.
- the EPA-rich microbial oil is preferably a crude oil, for example, from the viewpoint of increasing the purity of EPA in the composition.
- “crude oil of microbial oil” refers to a composition that has been extracted from microbial biomass and has not undergone the purification process described below.
- extraction means that the structure of microorganisms in biomass is destroyed and oil components in the microorganisms are taken out. The extraction method and the like will be described later.
- “refined microbial oil” means a degumming process, a deoxidation process, a decolorization process using activated clay or activated carbon, a water washing process, a deodorizing process using steam distillation, etc. It refers to a composition obtained through a crude oil refining process for removing substances other than the target product such as phospholipids and sterols.
- each fatty acid may be present in any form of triglyceride, diglyceride and monoglyceride.
- the triglyceride content of the EPA-rich microbial oil can be 70% by weight or more, 75% by weight or more, 80% by weight or more, 90% by weight or more, or 95% by weight or more with respect to the total weight of the microorganisms.
- the triglyceride content of the EPA-rich microbial oil is 70% by weight or more, the hygroscopicity as the microbial oil is not too low, for example, good fluidity can be obtained.
- the triglyceride content in the EPA-rich microbial oil is 99% by weight or less of the total weight of the EPA-rich microbial oil. .
- the triglyceride content in the EPA-rich microbial oil is 100% by weight with respect to the total weight of the EPA-rich microbial oil, that is, the EPA-rich microbial oil is substantially free of components other than triglycerides. Need not be included.
- the triglyceride content in EPA-rich microbial oil is measured according to AOCS Recommended Practice Cd 11c-93 (1997), SAMPLING AND ANALYSIS OF COMMERCIAL FATS AND OILS, (American Oil Chemists'Society).
- the EPA-rich microbial oil can contain other components that are specific to microbial oils, can exhibit a fatty acid composition that is specific to microorganisms, or can contain other components that are specific to microorganisms and exhibit a unique fatty acid composition be able to.
- Other ingredients unique to microbial oils include phospholipids, free fatty acids, fatty acid esters, monoacylglycerols, diacylglycerols, triacylglycerols, sterols and sterol esters, carotenoids, xanthophylls, ubiquinones, hydrocarbons, isoprenoid-derived compounds and any of these A compound that has been metabolized can be mentioned.
- the organic solvent in the present specification means a hydrophobic or hydrophilic solvent other than fatty acid and having at least one carbon atom, and is polar solvent, nonpolar solvent, water miscible solvent, water immiscible Examples include solvents and combinations of two or more thereof.
- organic solvents include substituted or unsubstituted, saturated or unsaturated aliphatic hydrocarbons, aromatic hydrocarbons, alcohols, ethers, ketones, aldehydes, carboxylic acids, esters, nitriles, amides, etc. It may be used alone or in combination of two or more.
- the total content of residual organic solvent in the EPA-rich microbial oil can be 5000 ppm or less, 3000 ppm or less, 2000 ppm or less, or 1000 ppm or less.
- examples of the organic solvent having a low content include at least one selected from the group consisting of methanol, ethanol, acetone, and hexane. These organic solvents can be independently 500 ppm or less, 300 ppm or less, or 200 ppm or less.
- any of the contents of methanol, ethanol, acetone, and hexane in the high-concentration DHA-containing oil can be 500 ppm or less, 300 ppm or less, or 200 ppm or less.
- a method for producing a microbial oil according to an embodiment of the present disclosure includes: preparing a microorganism having the ability to produce both eicosapentaenoic acid and docosahexaenoic acid; and aerating environment of the prepared microorganism from 30 mL / min to 1500 mL / min below, it includes culturing in a medium containing glycerol, obtaining the EPA-rich microbial oil of the present disclosure from the biomass obtained after culturing, and optionally including other steps.
- the step of preparing a microorganism having the ability to produce both eicosapentaenoic acid and docosahexaenoic acid may be simply referred to as a “microbe preparation step”.
- the step of culturing in a medium containing glycerol in an aerated environment of 30 mL / min to 1500 mL / min may be simply referred to as “culture step”.
- the process of obtaining the EPA-rich microbial oil of the present disclosure from the biomass obtained after culturing may be simply referred to as “microbial oil acquisition process”.
- microorganisms having the ability to produce both EPA and DHA are prepared.
- the microorganism having the ability to produce both EPA and DHA is not particularly limited as long as it is a microorganism capable of producing EPA and DHA inside the microorganism.
- the microorganism can be a culturable microorganism, and may be a microorganism after natural collection or a microorganism after culturing as long as it can be cultivated. These microorganisms may be used alone or in combinations of two or more.
- the microorganism having the ability to produce both EPA and DHA according to an embodiment of the present disclosure may be a gene recombinant.
- Examples of applicable microorganisms include at least one selected from the group consisting of microorganisms belonging to fungi, microorganisms of green algae (Chlorophycea), microorganisms of Euglena algae (Euglenida), and microorganisms of SAR. .
- yeast and filamentous fungi examples include yeast and filamentous fungi.
- the yeast is at least one microorganism selected from the group consisting of microorganisms belonging to the genus Yarrowia, microorganisms belonging to Pichia, microorganisms belonging to the genus Saccharomyces, microorganisms belonging to the genus Cryptococcus and microorganisms belonging to the genus Trichosporon.
- filamentous fungi include at least one microorganism selected from the group consisting of microorganisms belonging to the genus Mortierella, microorganisms belonging to the genus Phythium, and microorganisms belonging to the genus Phytophthora.
- microorganisms belonging to the genus Mortierella More preferred are microorganisms belonging to the genus Mortierella.
- Examples of microorganisms belonging to the genus Mortierella include Mortierella elongata, Mortierella exigua, Mortierella hygrophila and Mortierella alpina. it can.
- green algae microorganisms include microorganisms belonging to the genus Botryococcus, Pseudochorictis, and Squidemosmus (Scenedesmus and Desmodesmus).
- microorganisms of Euglena algae include microorganisms belonging to the family Euglenasae.
- Examples of the microorganism belonging to the euglena family include microorganisms belonging to the genus Euglena.
- SAR means SPR in the classification system proposed by Adl et al. (Adl et.al., Jornal of Eukaryotic Microbiology, 59 (5): 429-493 (2012)), specifically, Stramenopile, Albeolata And Rhizaria microorganisms. At least one microorganism selected from the group consisting of microorganisms belonging to stramenopile is preferred.
- Stramenopiles include Bicosoecida, Labyrinthula, Blastocystis, Actinophyida, Opalinata, Pacid et al, Pacid et ), Salmonellae (Hyphochytriomycetes), Velopayella, Chrysophyceae, Eustigatophyceae, Phaeotaphyceae, Phaeophyceae Sinurae (Sy urophyceae), yellow green algae (Xantexyophyceae), from brown algae (Phaeophyceae), Shizokuradia algae (Schizocladiophyceae), Kurisomerisu algae (Chrysomerophyceae), Dikuchioka algae (Dictyochophyceae), Borido algae (Bolidophiceae), Perago algae (Pelagophyceae) and diatoms (Bacillariophyceae) microorganisms Mention may be made of at least one microorganism selected
- albeolata examples include microorganisms belonging to Ciliophora, Apicomplexa, and Dinoflagellate.
- dinoflagellates examples include microorganisms belonging to the genus Crypthecodinium.
- microorganisms belonging to the genus Crypthecodinium examples include Crypthecodinium cohni.
- microorganisms belonging to Labyrinthula are preferable, and among them, microorganisms belonging to the family Thraustochtrid are particularly preferable.
- microorganisms belonging to the genus Cerebrumaceae include, for example, the genus Aplanochytrium, the genus Japonochytrium, the genus Labyrinthuroides, and the genus Schizocyttrium.
- Genus (Ulkenia), Aurantiochytrium, Oblongichytrium, Botryochyttrium, Parietiochytrium Preferred Ku, at least one microorganism selected from the group especially consisting Schizochytrium and Thraustochytrium microorganism among them is preferable.
- a microorganism capable of producing both EPA and DHA is a microorganism that does not grow or can produce more DHA than EPA among the above-described microorganisms in a medium containing glucose.
- Glucose is a saccharide that can be used in a medium as a carbon source or for other uses.
- microorganisms that do not proliferate or that can produce more DHA than EPA show different behavior from the case of culturing in a medium containing glucose in a specific culturing step described below. More EPA can be generated.
- microorganisms that have been considered to have poor EPA production efficiency can be used as microorganisms that are excellent in EPA production efficiency.
- Glucose-containing medium means a medium having a glucose content of 1 to 50% by weight, preferably 10 to 30% by weight, based on the total weight of the medium. The medium will be described later. “Does not grow in a medium containing glucose” means that the concentration of glucose in the culture medium is compared with the concentration added to the medium after a certain period of time, for example, 24 hours, under conditions that allow the growth of microorganisms. Means it has not decreased. Therefore, “does not grow in a medium containing glucose” means that it cannot grow when it contains only glucose as a carbon source. A method for confirming that “DHA can be produced more than EPA” can be performed based on the fatty acid content in the microbial oil obtained by culturing.
- the prepared microorganisms are cultured in a medium containing glycerol in an aeration environment of 30 mL / min to 1500 mL / min.
- the incubator used for the culture is not particularly limited and can be appropriately selected from incubators capable of liquid culture at a scale of 1 mL to 10 L or 100 mL to 1 L based on the type of microorganism.
- the incubator can be equipped with a stirring or osmotic function.
- a test tube, a flask, a Sakaguchi flask, a baffled flask, a tube type incubator, a raceway type incubator, a panel type incubator, or the like can be used.
- culturing under an aeration environment of 30 mL / min or more and 1500 mL / min or less corresponds to an appropriate aeration condition rather than a completely sealed condition, and can suppress excessive water evaporation.
- This aeration environment can be confirmed by closing the vent of the incubator with a stopper and measuring the flow rate at 26 mm water column (255 Pa) with a floating flow meter.
- the aeration environment of the culture process may be an environment in which an aeration rate of 30 mL / min or more and 1500 mL / min or less can be confirmed.
- the air flow rate is 30 mL / min or more and 200 mL or less, or 30 mL / min or more and 120 mL or less.
- This aeration environment can be achieved, for example, by closing the vent of the incubator with a plug that can provide the aeration environment defined in this specification.
- the stopper capable of providing this aeration environment can be selected by closing the vent of a 500 mL Erlenmeyer flask and measuring the flow rate at a 26 mm water column with a floating flow meter.
- a stopper that can block the vent of the incubator may be referred to as a “culture stopper”.
- This aeration environment preferably corresponds to an environment in which the amount of water evaporation is 0.5 mL when left at 30 ° C. for 10 days from the viewpoint of suppressing excessive concentration of the culture medium. .
- Examples of culture plugs that can provide an aeration environment in the culture process include “Shinetsu Silicosen T type” (T-42, Shin-Etsu Polymer Co., Ltd.) made of silicone rubber.
- the culture medium applied in the microorganism cultivation process contains glycerol.
- Glycerol in the culture medium usually acts as a carbon source, but may have other functions.
- the culture conditions and the like the culture medium and culture conditions that have been conventionally applied to the microorganism can be applied as they are.
- the content of glycerol in the culture medium can be 0.1% to 50% by weight, preferably 1% to 30% by weight, from the viewpoint of maintaining or promoting the growth of microorganisms.
- the carbon source can be added to the culture solution in an appropriate amount with no limitation on the number of times as the microorganism grows. When adding a carbon source, the amount of the carbon source added at a time can be appropriately set from the viewpoint of maintaining or promoting the growth of microorganisms.
- the culture medium is a glycerol as a main component and as a carbon source, for example, fructose, xylose, sucrose, maltose, starch, soluble starch, molasses, as long as the purpose of the method for producing EPA-rich microbial oil according to the present disclosure is not impaired.
- a carbon source for example, fructose, xylose, sucrose, maltose, starch, soluble starch, molasses, as long as the purpose of the method for producing EPA-rich microbial oil according to the present disclosure is not impaired.
- Glucose, trehalose, mannitol, and other compounds that can be used as a carbon source When these carbon sources are used in combination with glycerol, the total content of these carbon sources in the culture medium is 0.01 or more with respect to the content of glycerol, and 0.5% Hereinafter, it can be preferably 0.3 or less.
- the culture medium containing glycerol may contain glucose at a glucose concentration at which microorganisms grow and the content of eicosapentaenoic acid in the microbial oil is higher than the content of docosahexaenoic acid.
- culturing is started by inoculating a liquid medium or a solid medium with a spore, a mycelium of a strain, or a preculture obtained by culturing a microorganism in advance.
- the culture medium for example, yeast extract, malt extract, meat extract, fish extract, corn steep liquor, peptone, polypeptone, soybean flour, defatted soybean flour, casamino acid, urea, sodium glutamate, ammonium acetate, ammonium sulfate, ammonium nitrate, Ammonium chloride, sodium nitrate, etc .; inorganic salts such as sodium chloride, potassium chloride, magnesium chloride, magnesium sulfate, calcium chloride, potassium dihydrogen phosphate, dipotassium hydrogen phosphate, etc .; a medium in which vitamins and other necessary components are appropriately combined Can be mentioned.
- a medium containing sodium chloride, potassium chloride, magnesium chloride, magnesium sulfate, calcium chloride By using
- the nitrogen source in the culture medium can be 0.01% to 10% by weight, preferably 0.1% to 4% by weight, from the viewpoint of maintaining or promoting the growth of microorganisms.
- Nitrogen source can be added to the culture solution in an appropriate amount without any limitation as the microorganism grows.
- the amount of the nitrogen source added at a time can be appropriately set from the viewpoint of maintaining or promoting the growth of microorganisms.
- glycerol / yeast extract agar medium can be used from the viewpoint of the possibility of growth of microorganisms capable of producing a wide variety of EPA-rich microbial oils.
- the aqueous medium used as the base material of the liquid medium is basically water, and distilled water or purified water can be used. After preparation, the medium is adjusted to a pH of 3.0 to 9.0 and then sterilized by an autoclave or the like.
- the pH of the culture medium can be appropriately selected from the viewpoints of growth of microorganisms, synthesis of fatty acids, and maintenance or promotion of the ability to produce EPA, and is, for example, 3.0 to 9.5, preferably 3.5 to 9. 5, more preferably 4.5 to 9.0.
- the pH of the culture medium can be appropriately controlled with a pH adjuster such as sodium hydroxide or sulfuric acid when the components in the medium fluctuate due to metabolism by microorganisms.
- the culture temperature from the viewpoint of EPA production efficiency, for example, it can be 40 ° C. or lower, 35 ° C. or lower, 30 ° C. or lower, 28 ° C. or lower, or 25 ° C. or lower. It can be set to 8 ° C or higher, 10 ° C or higher, or 15 ° C or higher.
- the upper limit or lower limit of the culture temperature may be any combination, for example, 8 ° C to 40 ° C, 8 ° C to 28 ° C, 10 ° C to 40 ° C, 10 ° C to 25 ° C, 15 ° C to 25 ° C. it can. When culturing in such a temperature range, the concentration of EPA in the EPA-rich microbial oil can be increased.
- the culturing period in the culturing process varies depending on the type of microorganism, growth state, fatty acid accumulation efficiency, etc., and is not particularly limited, but may be terminated when the amount of dry biomass per liter of culture solution reaches 1 to 100 g. it can.
- the culturing period in the culturing step can usually be 1 day to 30 days, or 3 days to 10 days.
- the EPA-rich microbial oil of the present disclosure is obtained from the biomass obtained by culturing.
- the microbial oil acquisition step can include a recovery step of recovering biomass after the culture period and an extraction step of extracting microbial oil from the recovered biomass.
- the cultured biomass can be recovered from the medium by a method known in the art depending on the type of organism and the type of medium.
- biomass containing EPA-rich microbial oil is obtained.
- the recovery treatment can be generally performed from the culture solution using a solid-liquid separation means such as centrifugation and filtration after the completion of the culture.
- the solid medium and the biomass can be crushed with a homogenizer or the like without separating the biomass and the medium, and the resulting crushed product can be subjected to a subsequent extraction step.
- the extraction process oil is extracted from the biomass after the recovery process to obtain extracted oil.
- a conventional extraction method using an organic solvent can be usually applied.
- the extraction process may be an extraction process using supercritical carbon dioxide, or an extraction process using an organic solvent under a nitrogen stream.
- the organic solvent used for the extraction treatment include ethers such as dimethyl ether and diethyl ether; hydrocarbons having 10 or less carbon atoms such as petroleum ether, hexane and heptane; alcohols such as methanol and ethanol; chloroform; dichloromethane; fatty acids such as octanoic acid; The alkyl ester; fats and oils such as vegetable oil can be used.
- Extracted oil can be obtained by distilling off the organic solvent from the extract under reduced pressure.
- hexane is generally used as the organic solvent.
- the crude oil refers to the extracted oil obtained immediately after the extraction treatment.
- the wet cells When wet cells are used for the extraction treatment, the wet cells may be squeezed or a solvent may be used.
- the solvent that can be used include a solvent compatible with water such as methanol and ethanol, or a mixed solvent of a solvent compatible with water and water and / or another solvent. Other procedures are the same as described above.
- the method for producing the EPA-rich microbial oil is a degumming step, a deoxidizing step, and a decolorizing step after the extraction step. And a purification process including a deodorizing step.
- a EPA-rich microorganism that is a refined oil can be obtained.
- a triacylglycerol concentrate mainly having a higher triacylglycerol concentration than the crude oil can be obtained.
- degumming, deoxidation, decolorization, and deodorization are carried out by methods known to those skilled in the art using methods used for refining vegetable oil, fish oil, and the like on crude oil.
- the degumming process is performed by, for example, a water washing process.
- the deoxidation process is performed by, for example, a distillation process.
- the decoloring process is performed by, for example, a decoloring process using activated clay, activated carbon, silica gel, or the like.
- the deodorizing process is performed by, for example, steam distillation.
- the EPA-rich microbial oil obtained by the method for producing EPA-rich microbial oil is obtained by subjecting the crude oil or refined oil to hydrolysis, alkylation, after the extraction step in the microbial oil acquisition step, and optionally after the extraction step and the purification step. You may attach
- a composition containing free EPA derived from EPA-rich microbial oil, a composition containing lower alkyl ester EPA derived from EPA-rich microbial oil, and the like can be obtained.
- a composition containing a free fatty acid derived from the triacylglycerol concentrate obtained in the purification step a composition containing a fatty acid lower alkyl ester Can be obtained.
- the alkyl esterification treatment and hydrolysis treatment in the processing step can be performed under conditions known to those skilled in the art.
- a lower alcohol is used for the alkyl esterification treatment.
- lower alcohols include alcohols having 1 to 3 carbon atoms, such as methanol, ethanol, and propanol.
- the extracted oil is treated with anhydrous methanol-hydrochloric acid 5% -10%, BF 3 -methanol 10% -50%, etc. on a volume basis at room temperature for 1-24 hours. Can be obtained.
- the fatty acid ethyl ester it is obtained by treating the extracted oil with 1% to 20% ethanol sulfate at 25 to 100 ° C. for 15 to 60 minutes.
- the methyl ester or ethyl ester can be extracted from the reaction solution with an organic solvent such as hexane, diethyl ether, or ethyl acetate.
- the extract is dried with anhydrous sodium sulfate or the like, and the organic solvent is distilled off to obtain a composition containing fatty acid alkyl ester as a main component.
- the hydrolysis treatment may be performed under conditions known to those skilled in the art.
- the extracted oil is subjected to alkaline decomposition treatment with 5% sodium hydroxide at room temperature for 2 to 3 hours, and then the obtained decomposition is performed.
- a composition containing free fatty acid can be obtained by a method commonly used for extraction or purification of fatty acid.
- both alkyl esterification treatment and hydrolysis treatment may be performed.
- free fatty acids with higher purity can be obtained.
- an extraction treatment using an organic solvent such as ether or ethyl acetate may be performed.
- the EPA-rich microbial oil or the composition derived therefrom is used to reduce the concentration of fatty acids containing fatty acids other than EPA as a constituent fatty acid and to increase the concentration of EPA after the purification step described above or after processing.
- Concentration treatment can be included.
- distillation, rectification, column chromatography, low-temperature crystallization method, urea inclusion method, liquid-liquid countercurrent distribution chromatography, etc. may be applied singly or in combination of two or more. it can.
- a combination of distillation or rectification and column chromatography or liquid-liquid countercurrent chromatography is preferred.
- column chromatography column chromatography of a reverse phase distribution system is preferable.
- the content of EPA that can be finally contained in the EPA-rich microbial oil is increased, and the content of fatty acids other than EPA in the fatty acid is increased. The amount can be reduced.
- the pressure at the top of the distillation column is reduced to 10 mmHg (1333 Pa) or lower, and the column bottom temperature is 165 ° C. to 210 ° C., preferably 170 ° C. to 195 ° C. Distilling under conditions is preferable from the viewpoint of suppressing fatty acid denaturation by heat and increasing the rectification efficiency.
- the reverse phase column chromatography examples include reverse phase column chromatography known in the art, and in particular, high performance liquid chromatography (HPLC) using a base material modified with octadecylsilyl group (ODS) as a stationary phase.
- HPLC high performance liquid chromatography
- ODS octadecylsilyl group
- the EPA concentration is, for example, 90% to 98%, 95% to 98%, 96% to 98% or 97% by weight of the total weight of fatty acids in the oil. % To 98% by weight of EPA concentrated oil can be obtained.
- Another aspect of the present invention includes a method for controlling the fatty acid content ratio of a microbial oil.
- the method for controlling the fatty acid content ratio of a microbial oil according to the present disclosure provides a microorganism that can produce a microbial oil that does not grow or contains more docosahexaenoic acid than eicosapentaenoic acid in a medium containing glucose.
- the prepared microorganism is cultured in a culture medium containing glycerol in an aeration environment of 30 mL / min to 1500 mL / min, and more eicosapentaenoic acid than docosahexaenoic acid is obtained from the biomass obtained by the culture.
- the fatty acid composition of microbial oil produced by a specific microorganism can be easily controlled.
- the selection range of the microbial species that can be used to efficiently obtain an EPA-containing composition such as EPA-rich microbial oil can be expanded.
- “Control of fatty acid composition of microbial oil” in the present embodiment means that the fatty acid composition of microbial oil that can be produced by a microorganism is changed according to the conditions under which the microorganism is cultured.
- the aspect which the microorganisms which do not grow in this embodiment change to the state which can produce microbial oil which has a predetermined fatty acid composition is also contained in one aspect
- a microorganism capable of producing a microbial oil that does not grow in a medium containing glucose or contains more docosahexaenoic acid than eicosapentaenoic acid is prepared.
- the “microorganisms that do not grow in a medium containing glucose or can produce microbial oil containing more docosahexaenoic acid than eicosapentaenoic acid” used in this step are microbial oils according to other embodiments of the present disclosure.
- the microorganism described in the “microbe preparation step” in the production method is applicable.
- the prepared microorganism is then cultured in a culture medium containing glycerol in an aerated environment of 30 mL / min to 1500 mL / min, preferably 30 mL / min to 120 mL / min.
- a culture medium containing glycerol in an aerated environment of 30 mL / min to 1500 mL / min, preferably 30 mL / min to 120 mL / min.
- a microbial oil containing more eicosapentaenoic acid than docosahexaenoic acid is obtained from the biomass obtained by culturing.
- the microbial oil obtained here is a microbial oil having a different content ratio of DHA and EPA from the microbial oil obtained when cultured in a culture medium containing glucose.
- the matter described in the “microbe oil obtaining step” in the method for producing a microbial oil according to another embodiment of the present disclosure can be applied to the matter regarding this step.
- EPA-rich microbial oil can be applied to uses that require efficient intake of various EPA functions.
- the product containing EPA-rich microbial oil include foods, supplements, pharmaceuticals, cosmetics, and feeds.
- EPA-rich microbial oils can be used in the production methods of these products.
- the use of EPA-rich microbial oils includes, in particular, prevention of lifestyle-related diseases such as arteriosclerosis, cerebral infarction, myocardial infarction, thrombosis, hyperlipidemia, metabolic syndrome improvement, antiallergy,
- Examples include foods, supplements, pharmaceuticals, cosmetics, and feeds that can be expected to have effects such as inflammation, anticancer, and dementia.
- pharmaceuticals include skin external preparations and oral preparations.
- the form of use of the EPA-rich microbial oil is not particularly limited, and can be used as a liquid component or as a solid component.
- EPA-rich microbial oil when EPA-rich microbial oil is applied to products such as foods, supplements, pharmaceuticals, cosmetics, and feeds, the EPA-rich microbial oil itself may be combined with other optional components to produce a product. Any additional processing can be performed and commercialized before or after combining with the components. Examples of such additional treatment include powdering, pelletizing, encapsulation, and tableting.
- the medicine When using EPA-rich microbial oil as a medicine, the medicine contains EPA-rich microbial oil, a pharmaceutically acceptable carrier, and other components as necessary.
- the administration form may be any form as long as oral administration or parenteral administration is conveniently performed. Examples of dosage forms include injections, infusions, powders, granules, tablets, capsules, enteric solvents, troches, liquids for internal use, suspensions, emulsions, syrups, liquids for external use, poultices, nasal drops, dots Examples include ear drops, eye drops, inhalants, ointments, lotions, suppositories, and the like, and these can be used alone or in combination depending on the symptoms.
- the dose varies depending on the purpose of administration and the situation of the subject of administration, such as sex, age, body weight, etc., but usually when administered orally to an adult, the total amount of EPA as a structured lipid per day In the range of 0.01 mg to 10 g, preferably 0.1 mg to 2 g, more preferably 1 mg to 200 mg, and in the case of parenteral administration, the total amount of EPA as structured lipid is 0.001 mg to 1 g per day, preferably Can be appropriately adjusted in the range of 0.01 mg to 200 mg, more preferably 0.1 mg to 100 mg.
- each feature of the invention described in one embodiment (embodiment) regarding each aspect of the present disclosure may be arbitrarily combined to form a new embodiment. It is to be understood that any new embodiment may be encompassed by each aspect of the present disclosure.
- a numerical range formed by combining an upper limit value arbitrarily selected from one or more upper limit values and a lower limit value arbitrarily selected from one or more lower limit values is also included in one aspect of the present invention.
- cell or “bacteria” means a collection of cells or fungus unless otherwise specified, and corresponds to biomass in the present specification.
- Example 1 “SEK 704 AB97560 strain” (Aquat. Microb. Ecol., 2015, Vol. 74, pp. 187-204), which is a related species of Thraustochytrium sp. AR2-1 AB810959 It was obtained from the National Institute of Technology and Evaluation Biotechnology Center (unidentified Thraustochytrid 5, NBRC 110858, hereinafter referred to as “microorganism A”).
- microorganism A After suspending microorganism A in 50% artificial seawater to be described later, 0.1 ml of this microorganism suspension is sterilized with 500 mL folds containing 100 mL of a liquid medium for jellyfish fungus having the following composition (pH is 6.8). Inoculated into shake flask. 50% artificial seawater was prepared by mixing the Herbst formulation shown in Table 4 and purified water at a volume ratio of 1: 1. The mouth of the flask after inoculation with the fungus was closed using a silicone rubber culture stopper “Shinetsu Silicosen T type” (Shin-Etsu Polymer Co., Ltd.).
- “Shinetsu Silicosen T type” shows a ventilation rate of 30 to 120 mL / min when the flow rate of a 26 mm water column is measured with a floating flowmeter by closing the vent of a 500 mL Erlenmeyer flask. Inject 5 mL of water, leave it with a culture stopper, and show the amount of water evaporation of 0.5 mL or less at 30 ° C. for 10 days when the change in weight due to water evaporation is measured over time. Bio-Shaker BR-300LF (Tytec Co., Ltd.) was used as a culture apparatus, and the flask was shaken at 28 ° C. and 130 rpm for 3 days.
- the microbial oil A (T type) contained 40.3% by area of EPA with respect to all fatty acids and 21.3% by area of DHA with respect to all fatty acids.
- the ratio of the EPA content to the DHA content was 1.89.
- microbial oil A (C type) was obtained.
- microbial oil A (C type) was converted to FAME, and then subjected to fatty acid analysis.
- the microbial oil A (C type) obtained from the microorganism A contained 11.6 area% of EPA with respect to the total fatty acids and 52.1 area% with respect to the total fatty acids.
- the ratio of the EPA content to the DHA content was 0.22.
- the microorganism A is cultured in a culture medium containing glycerol instead of glucose in an aeration environment with an aeration rate of 30 to 120 mL / min, whereby the microorganism A containing more EPA than DHA ( It was found to produce (T type). Thereby, it was possible to obtain a microbial oil containing EPA at a high content of 38 area% or more and having a ratio of the content of EPA to the content of DHA of 1.7 or more.
- Example 2 Each microorganism was cultured in the same manner as in Example 1 except that the microorganism A and microorganisms B to G used in Example 1 listed below were used and the culture days were set to 5 days. G (Gly) was obtained.
- Microorganism A Unidentified Thraustochytrid5 (NBRC110858)
- Microorganism B Schizochytrium sp.
- Microorganism C Thraustochytrium aureum (ATCC 34304)
- Microorganism D Schizochytrium agregatum (ATCC 28209)
- Microorganism E Unidentified Thraustochytrid1 (NBRC110846)
- Microorganism F Thraustochytrium roseum (ATCC 28210)
- Microorganism G Thraustochytrium stratum (ATCC 24473)
- Tables 5 and 6 show the fatty acid compositions of microbial oils A (Gly) to G (Gly).
- the triglyceride content was 70% by weight or more.
- microbial oils A (Gly) to G (Gly) are all microbial oils containing 38% by area or more of EPA and more EPA than DHA. And a microbial oil having the fatty acid composition ratio shown in Table 6. Therefore, the microbial oils A (Gly) to G (Gly) contain EPA at a high concentration and have an advantage that the EPA function can be effectively exhibited.
- microorganisms A to G described above were used except for the microorganism oil A (Gly) described above except that a liquid medium for pH mold (pH 6.8) containing the same components except that the same amount of glucose was used instead of glycerol. Culturing was carried out in the same manner as that for obtaining G (Gly) to obtain microbial oils A (Glu) to G (Glu).
- the microorganism B, the microorganism C, the microorganism E, and the microorganism F are all microbial oil B (Glu), microbial oil containing more DHA than EPA in the culture medium using glucose as a carbon source. It was confirmed that C (Glu), microbial oil E (Glu) and microbial oil F (Glu) were produced. In addition, it was confirmed that the microorganism A, the microorganism D, and the microorganism G do not grow in the culture medium using glucose as a carbon source.
- microorganisms A to G were microorganisms that did not grow on a culture medium containing glucose as a carbon source or produced a microbial oil containing more DHA than EPA.
- microbial oils A (Gly) to G (Gly) contained more EPA than DHA.
- microbial oils having different fatty acid content ratios can be obtained by selecting predetermined culture conditions. Thereby, it turned out that the selection range of the microorganism species which can be utilized in order to obtain an EPA containing composition efficiently can be expanded easily. By using this microbial oil, EPA can be obtained more efficiently, and various products containing EPA can be efficiently provided.
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Wood Science & Technology (AREA)
- Health & Medical Sciences (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Botany (AREA)
- Biomedical Technology (AREA)
- Virology (AREA)
- Cell Biology (AREA)
- Medicinal Chemistry (AREA)
- Tropical Medicine & Parasitology (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Fats And Perfumes (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
特許文献2には、不飽和脂肪酸を含有する油脂をリパーゼによる加水分解反応に付す工程、及び、不飽和脂肪酸が濃縮されたグリセリド画分を分離する工程、を含む不飽和脂肪酸濃縮油の製造方法において、リパーゼによる加水分解反応の反応添加物として水酸化カルシウム、塩化マグネシウム、硫酸アンモニウム、炭酸カルシウム、リン酸二水素カリウム、塩化アンモニウムのいずれかを添加することを特徴とする方法が開示されている。
[1] エイコサペンタエン酸(EPA)及びドコサヘキサエン酸(DHA)を含み、 エイコサペンタエン酸の含有率が、全脂肪酸に対して38面積%以上であり、以下の(a)~(c)からなる群より選択される少なくともひとつの脂肪酸比を有する、微生物油:
(a) 1.7以上の、DHAの含有率に対するEPAの含有率の比、
(b) 0.3以下の、炭素数20の脂肪酸の含有率に対する炭素数18の脂肪酸の含有率の比、
(c) 1.5以下の、炭素数22の脂肪酸の含有率に対する炭素数18の脂肪酸の含有率の比。
[2] トリグリセリド含有率が、微生物油の全重量に対して70重量%以上である[1]に記載の微生物油。
[3] 飽和脂肪酸の含有率が、全脂肪酸に対して40面積%以下である[1]又は[2]に記載の微生物油。
[4] アラキドン酸(ARA)の含有率が、全脂肪酸に対して10.0面積%以下である[1]~[3]のいずれか1に記載の微生物油。
[5] アラキドン酸(ARA)の含有率が、EPAの含有率に対して5.0以下である[1]~[4]のいずれか1に記載の微生物油。
[6] ドコサヘキサエン酸の含有率が、エイコサペンタエン酸の含有率よりも低い[1]~[5]のいずれか1に記載の微生物油。
[7] ドコサヘキサエン酸の含有率が、全脂肪酸に対して0.5面積%以上25面積%以下である[1]~[6]のいずれか1に記載の微生物油。
[8] n-6ドコサペンタエン酸(n-6DPA)の含有率が、n-3ドコサペンタエン酸(n-3DPA)の含有率に対して2.0以下である[1]~[7]のいずれか1に記載の微生物油。
[9] n-3ドコサペンタエン酸(n-3DPA)の含有率が、全脂肪酸に対して0.3面積%以上である[1]~[8]のいずれか1に記載の微生物油。
[10] エイコサテトラエン酸(ETA)の含有率が、全脂肪酸に対して0.1面積%以上である[1]~[9]のいずれか1に記載の微生物油。
[11] 炭素数18の不飽和脂肪酸の合計含有率が、それぞれ全脂肪酸に対して2.0面積%以下である[1]~[10]のいずれか1に記載の微生物油。
[12] 粗油である[1]~[11]のいずれか1に記載の微生物油。
[13] エイコサペンタエン酸及びドコサヘキサエン酸双方の生成能を有する微生物を用意すること、用意された微生物を、30mL/分以上1500mL/分以下の通気環境下において、グリセロールを含有する培養培地中で培養すること、培養により得られたバイオマスから、請求項1~請求項12のいずれか1に記載の微生物油を得ること、を含む、微生物油の製造方法。
[14] 前記微生物が、ストラメノパイル(Stramenopiles)に属する微生物からなる群より選択される少なくとも1種の微生物である[13]に記載の微生物油の製造方法。
[15] 前記微生物が、グルコースを含有する培地中では、増殖しないか、ドコサヘキサエン酸を、エイコサペンタエン酸よりも多く生成し得る微生物である[13]又は[14]のいずれか1に記載の微生物油の製造方法。
[16] 前記培養の環境が、30℃で10日間放置したときに0.5mLの水分蒸発量に相当する環境である[13]~[15]のいずれか1に記載の微生物油の製造方法。
[17] [13]~[16]のいずれか1に記載の製造方法により得られる微生物油。
[18] グルコースを含有する培地中では、増殖しないか、ドコサヘキサエン酸を、エイコサペンタエン酸よりも多く含む微生物油を生成し得る微生物を用意すること、用意された微生物を、30mL/分以上1500mL/分以下の通気環境下において、グリセロールを含有する培養培地中で培養すること、培養により得られたバイオマスから、エイコサペンタエン酸を、ドコサヘキサエン酸よりも多く含有する微生物油を得ること、を含む、微生物油の脂肪酸含有比を制御する方法。
(a) 1.7以上の、DHAの含有率に対するEPAの含有率の比、
(b) 0.3以下の、炭素数20の脂肪酸の含有率に対する炭素数18の脂肪酸の含有率の比、
(c) 1.5以下の、炭素数22の脂肪酸の含有率に対する炭素数18の脂肪酸の含有率の比。
これを更に説明すれば、本開示の微生物油がDHAの含有率に対するEPAの含有率の比を一定以上の場合、EPAの所望の機能を効果的に発揮することができる。また、EPAと共にDHAも含むので、DHAとEPAとの相乗効果も期待できる。
炭素数18の飽和又は不飽和脂肪酸は、炭素数20以上の多価不飽和脂肪酸の前駆体として知られている。このため、本開示の微生物油において、このような炭素数18の飽和又は不飽和脂肪酸の含有率が、炭素数20の脂肪酸又は炭素数22の脂肪酸の含有率に対して一定以下の比となる場合、EPA及びDHAを得るために効率よく利用されて、微生物油中に高純度にEPA及びDHAを含むことができる。本開示の微生物油は、炭素数18の脂肪酸の含有率が所定の範囲に抑えられているか、共に生成され得るDHAの含有率が所定範囲となっているので、EPAのより効率よい機能発揮が期待できる。
本明細書では、EPA及びDHAを含み、EPAの含有率が全脂肪酸に対して38面積%以上であり、所定の要件を備えた本開示に係る微生物油を「EPA高含有微生物油」と称する場合がある。
本開示に係る微生物油の製造方法では、EPAとDHAとを生成可能な微生物を、所定の通気環境下でかつグリセロールを含有する培地中で培養することを含む。これより、本開示に係るEPA高含有微生物油を効率よく得ることができる。
本開示にかかる微生物油の製造方法において用いるグリセロールを含有する培養培地は、微生物が増殖し、微生物油のエイコサペンタエン酸の含有率がドコサヘキサエン酸の含有率よりも高くなるグルコース濃度でグルコースを含んでもよい。
この文脈において、「炭素数20の脂肪酸」のように炭素数と用語「脂肪酸」との組み合わせによる表現は、当該炭素数を有する飽和脂肪酸と、当該炭素数を有する一価以上の飽和脂肪酸との総称を意味するために用いられる場合がある。たとえば「炭素数20の脂肪酸」の用語には、炭素数20の飽和脂肪酸、炭素数20の一価の不飽和脂肪酸、炭素数20の二価以上の不飽和脂肪酸が含まれる。
以下、本開示について説明する。
本開示の一実施形態であるEPA高含有微生物油は、エイコサペンタエン酸(EPA)及びドコサヘキサエン酸(DHA)を含み、エイコサペンタエン酸の含有率が、全脂肪酸に対して38面積%以上であり、以下の(a)~(c)からなる群から選択される少なくともひとつの脂肪酸比を有する、微生物油:
(a) 1.7以上の、DHAの含有率に対するEPAの含有率の比、
(b) 0.3以下の、炭素数20の脂肪酸の含有率に対する炭素数18の脂肪酸の含有率の比、
(c) 1.5以下の、炭素数22の脂肪酸の含有率に対する炭素数18の脂肪酸の含有率の比。
(c) EPA高含有微生物油において、炭素数18の脂肪酸の含有率は、DHAのEPAに対する相乗効果の効果的な発揮の観点からの観点から、炭素数22の脂肪酸の含有率に対して1.5以下、1.0以下、0.5以下、0.1以下、0.08以下、又は0.05以下とすることができる。
EPA高含有微生物において、炭素数18の脂肪酸は含まれてなくてもよく、したがって、炭素数18の脂肪酸の含有率の下限値は0面積%であってもよい。
EPA高含有微生物は、(a)~(c)に加えて、更に以下(d)~(n)からなる群より選択される少なくともひとつの脂肪酸含有率又は比を有してもよい。
(d’) EPA高含有微生物油において、PUFAの安定性が良好である低温での取り扱い性が優れるという観点から、EPAに対する飽和脂肪酸の含有率の比は、1.5以下、1.1以下、0.8以下、0.5以下、又は0.4以下とすることができる。
EPA高含有微生物油に含まれうる飽和脂肪酸としては、たとえば、炭素数12以上の飽和脂肪酸を挙げることができる。炭素数12以上の飽和脂肪酸としては、たとえばラウリン酸(C12:0)、ミリスチン酸(C14:0)、パルミチン酸(C16:0)、ステアリン酸(C18:0)、アラキジン酸(C20:0)、ベヘン酸(C22:0)、リグノセリン酸(C24:0)を挙げることができる。
(e’) EPA高含有微生物油において、n-6PUFAによる拮抗作用の観点から、EPAに対するARAの含有率の比は、5.0以下、1.0以下、0.5以下、0.1以下、0.08以下、0.05以下、又は0.04以下とすることができる。
EPA高含有微生物においてETAの含有率の範囲は、これらの上限値及び下限値の任意の組み合わせとすることができ、たとえば、0.1面積%以上10.0面積%以下、又は0.5面積%以上5.0面積%以下とすることができる。
EPA高含有微生物においてETA/EPA比の範囲は、これらの上限値及び下限値の任意の組み合わせとすることができ、たとえば、0.001以上1.6以下、又は0.001以上1.0以下とすることができる。
(h’) EPA高含有微生物油において、EPAの機能性発揮、精製効率等の観点から、EPAに対するn-3DPAの含有率の比は、8.0以下、6.0以下、又は5.0以下とすることができる。
(i’) EPA高含有微生物油において、n-6PUFAによる拮抗作用の観点から、EPAに対するn-6PDAの含有率の比は、1.0以下、0.1以下、又は0.01以下とすることができる。
(k’) EPA高含有微生物油において、EPAの機能性発揮、精製効率向上等の観点から、EPAに対する炭素数18の不飽和脂肪酸の合計含有率の比は、2.0以下、1.0以下、0.1以下、0.05以下、0.02以下又は0.01以下とすることができる。
(l’) EPA高含有微生物油において、低温での安定性及び取り扱い性の観点から、EPAに対する炭素数21の脂肪酸の含有率の比は、1.0以下、0.1以下、又は0.02以下とすることができる。
(m’) EPA高含有微生物油において、n-6PUFAによる拮抗作用の観点から、EPAに対するDGLAの脂肪酸の含有率の比は、1.0以下、0.1以下、0.05以下、又は0.01以下とすることができる。
(n’) EPA高含有微生物油において、n-6PUFAによる拮抗作用の観点から、EPAに対するDTAの脂肪酸の含有率の比は、1.0以下、0.1以下、0.05以下、又は0.02以下とすることができる。
EPA高含有微生物油において、含有量が低い有機溶媒としては、メタノール、エタノール、アセトン及びヘキサンからなる群より選択される少なくとも1つを挙げることができる。これらの有機溶媒は、それぞれ独立に、500ppm以下、300ppm以下、又は200ppm以下とすることができる。たとえば、高濃度DHA含有油におけるメタノール、エタノール、アセトン及びヘキサンの含有量のいずれもが、500ppm以下、300ppm以下、又は200ppm以下とすることができる。
本開示の一実施形態に係る微生物油の製造方法は、エイコサペンタエン酸及びドコサヘキサエン酸双方の生成能を有する微生物を用意すること、用意された微生物を、30mL/分以上1500mL/分以下の通気環境下において、グリセロールを含有する培地中で培養すること、培養後に得られたバイオマスから、本開示のEPA高含有微生物油を得ることを含み、必要に応じて他の工程を含む。
本明細書では、エイコサペンタエン酸及びドコサヘキサエン酸双方の生成能を有する微生物を用意する工程を、単に、「微生物用意工程」と称する場合がある。30mL/分以上1500mL/分以下の通気環境下において、グリセロールを含有する培地中で培養する工程を、単に「培養工程」という場合がある。培養後に得られたバイオマスから、本開示のEPA高含有微生物油を得る工程を、単に、「微生物油取得工程」という場合がある。
このような濃縮処理を行うことによって、EPA濃度が、たとえば、油中の脂肪酸の合計重量の90重量%~98重量%、95重量%~98重量%、96重量%~98重量%又は97重量%~98重量%のEPA濃縮油を得ることができる。
本明細書において、同一の対象について言及された1若しくは複数の上限値のみを規定する数値範囲と1若しくは複数の下限値のみを規定する数値範囲とが記載されている場合、特に断らない限り、1又は複数の上限値から任意に選択された上限値と、1又は複数の下限値から任意に選択された下限値とを組み合わせて成立する数値範囲も、本発明の一形態に含まれる。
以下の実施例の項において「細胞」又は「菌体」とは、特に断りのない限り、細胞又は菌体の集合物を意味し、本明細書におけるバイオマスに相当する。
ヤブレツボカビ科であるスラウストキトリウム属(Thraustochytriumsp.)AR2-1 AB810959の類縁種である「SEK 704 AB973560株」(Aquat. Microb. Ecol., 2015, Vol.74, pp.187-204)を、独立行政法人製品評価技術基盤機構 バイオテクノロジーセンターより入手した(未同定Thraustochytrid5、NBRC110858、以下微生物Aという)。
菌を接種した後のフラスコの口を、シリコーンゴム製の培養栓「シンエツ シリコセン Tタイプ」(信越ポリマー株式会社)を用いて塞いだ。「シンエツ シリコセン Tタイプ」は、500mLの三角フラスコの通気口を塞ぎ、26mm水柱時の流量を浮遊式流量計で測定した場合に30~120mL/分の通気量を示し、また、中試験管に水5mLを注入し、培養栓を付して放置し、水分蒸発による重量の増減を経時的に測定した場合に、30℃10日で0.5mL以下の水分蒸発量を示す。培養装置には、Bio-Shaker BR-300LF(タイテック株式会社)を使用し、このフラスコを3日間、28℃、130rpmで振とうした。
得られた凍結乾燥菌体から、以下のようにして、総脂質、即ち微生物油A(Tタイプ)を得て、その後さらに、得られた微生物油A(Tタイプ)を脂肪酸メチルエステルへと変換した。
クロロホルム:メタノール(2:1、v/v)で凍結乾燥菌体から総脂質を抽出した。得られた総脂質に対し、メチルエステル化して、脂肪酸メチルエステル(FAME)を得た。得られたFAMEに対して、ガスクロマトグラフィーによりFAME分析を行った。ガスクロマトグラフの条件は以下のとおりに設定した。
・カラム DB-WAX 0.530mm×30m、フィルム厚1.00μm(アジレント・テクノロジー株式会社)
・キャリアーガス条件 ヘリウム 1.0ml/分、分離比100:1
・カラム温度条件 140℃で5分、240℃まで4℃/分で昇温、240℃で10分・検出 FID
・検出器温度 260℃
・注入口温度 250℃
・注入量 1μL
その結果、微生物Aから得られた微生物油A(Cタイプ)は、EPAを全脂肪酸に対して11.6面積%、DHAを全脂肪酸に対して52.1面積%含有していた。DHAの含有率の対するEPAの含有率の比は、0.22であった。
これにより、EPAを38面積%以上の高含有率で含み、DHAの含有率に対するEPAの含有率の比が1.7以上の微生物油を得ることができた。
以下に挙げる実施例1で用いた微生物Aと微生物B~Gを使用し、培養日数を5日間とした以外は、実施例1と同様にして各微生物を培養して微生物油A(Gly)~G(Gly)を得た。
微生物A:未同定Thraustochytrid5(NBRC110858)
微生物B:Schizochytrium sp.(NBRC102615)
微生物C:Thraustochytrium aureum(ATCC34304)
微生物D:Schizochytrium aggregatum(ATCC28209)
微生物E:未同定 Thraustochytrid1(NBRC110846)
微生物F:Thraustochytrium roseum(ATCC28210)
微生物G:Thraustochytrium striatum(ATCC24473)
また、微生物油A(Gly)~G(Gly)については、トリグリセリド含有率はいずれも70重量%以上であった。
表7及び表8に示すとおり、微生物B、微生物C、微生物E及び微生物Fは、いずれもグルコースを炭素源とする培養培地では、EPAよりもDHAを多く含む微生物油B(Glu)、微生物油C(Glu)、微生物油E(Glu)及び微生物油F(Glu)を生成することが確認された。なお、微生物A、微生物D及び微生物Gは、グルコースを炭素源とする培養培地では、増殖しないことが確認された。
このように、所定の培養条件を選択することによって、異なる脂肪酸含有比を有する微生物油を得ることができることがわかった。これにより、EPA含有組成物を効率よく得るために利用可能な微生物種の選択範囲を、簡便に拡大することができることがわかった。
この微生物油を用いることによって、EPAをより効率よく得ることができ、また、EPAを含有する各種製品を効率よく提供することができる。
Claims (18)
- エイコサペンタエン酸(EPA)及びドコサヘキサエン酸(DHA)を含み、
エイコサペンタエン酸の含有率が、全脂肪酸に対して38面積%以上であり、
以下の(a)~(c)からなる群より選択される少なくともひとつの脂肪酸比を有する、微生物油:
(a) 1.7以上の、DHAの含有率に対するEPAの含有率の比、
(b) 0.3以下の、炭素数20の脂肪酸の含有率に対する炭素数18の脂肪酸の含有率の比、
(c) 1.5以下の、炭素数22の脂肪酸の含有率に対する炭素数18の脂肪酸の含有率の比。 - トリグリセリド含有率が、微生物油の全重量に対して70重量%以上である請求項1記載の微生物油。
- 飽和脂肪酸の含有率が、全脂肪酸に対して40面積%以下である請求項1又は請求項2記載の微生物油。
- アラキドン酸(ARA)の含有率が、全脂肪酸に対して10.0面積%以下である請求項1~請求項3のいずれか1項記載の微生物油。
- アラキドン酸(ARA)の含有率が、EPAの含有率に対して5.0以下である請求項1~請求項4のいずれか1項記載の微生物油。
- ドコサヘキサエン酸の含有率が、エイコサペンタエン酸の含有率よりも低い請求項1~請求項5のいずれか1項記載の微生物油。
- ドコサヘキサエン酸の含有率が、全脂肪酸に対して0.5面積%以上25面積%以下である請求項1~請求項6のいずれか1項記載の微生物油。
- n-6ドコサペンタエン酸(n-6DPA)の含有率が、n-3ドコサペンタエン酸(n-3DPA)の含有率に対して2.0以下である請求項1~請求項7のいずれか1項記載の微生物油。
- n-3ドコサペンタエン酸(n-3DPA)の含有率が、全脂肪酸に対して0.3面積%以上である請求項1~請求項8のいずれか1項記載の微生物油。
- エイコサテトラエン酸(ETA)の含有率が、全脂肪酸に対して0.1面積%以上である請求項1~請求項9のいずれか1項記載の微生物油。
- 炭素数18の不飽和脂肪酸の合計含有率が、それぞれ全脂肪酸に対して2.0面積%以下である請求項1~請求項10のいずれか1項記載の微生物油。
- 粗油である請求項1~請求項11のいずれか1項記載の微生物油。
- エイコサペンタエン酸及びドコサヘキサエン酸双方の生成能を有する微生物を用意すること、
用意された微生物を、30mL/分以上1500mL/分以下の通気環境下において、グリセロールを含有する培養培地中で培養すること、
培養により得られたバイオマスから、請求項1~請求項12のいずれか1項記載の微生物油を得ること、
を含む、微生物油の製造方法。 - 前記微生物が、ストラメノパイル(Stramenopiles)に属する微生物からなる群より選択される少なくとも1種の微生物である請求項13記載の微生物油の製造方法。
- 前記微生物が、グルコースを含有する培地中では、増殖しないか、ドコサヘキサエン酸を、エイコサペンタエン酸よりも多く生成し得る微生物である請求項13又は請求項14記載の微生物油の製造方法。
- 前記培養の環境が、30℃で10日間放置したときに0.5mLの水分蒸発量に相当する環境である請求項13~請求項15のいずれか1項記載の微生物油の製造方法。
- 請求項13~請求項16のいずれか1項記載の製造方法により得られる微生物油。
- グルコースを含有する培地中では、増殖しないか、ドコサヘキサエン酸を、エイコサペンタエン酸よりも多く含む微生物油を生成し得る微生物を用意すること、
用意された微生物を、30mL/分以上1500mL/分以下の通気環境下において、グリセロールを含有する培養培地中で培養すること、
培養により得られたバイオマスから、エイコサペンタエン酸を、ドコサヘキサエン酸よりも多く含有する微生物油を得ること、
を含む、微生物油の脂肪酸含有比を制御する方法。
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP22214693.8A EP4219732A3 (en) | 2018-04-26 | 2019-04-26 | Microbial oil and method for producing microbial oil |
JP2020515620A JP7394748B2 (ja) | 2018-04-26 | 2019-04-26 | 微生物油及び微生物油の製造方法 |
EP19792171.1A EP3786301A4 (en) | 2018-04-26 | 2019-04-26 | MICROBIAL OIL AND METHOD FOR PRODUCTION OF MICROBIAL OIL |
US17/050,133 US20210047663A1 (en) | 2018-04-26 | 2019-04-26 | Microbial oil/lipid and method for producing microbial oil/lipid |
US18/529,012 US20240117390A1 (en) | 2018-04-26 | 2023-12-05 | Microbial Oil/Lipid and Method for Producing Microbial Oil/Lipid |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2018085751 | 2018-04-26 | ||
JP2018-085751 | 2018-04-26 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US17/050,133 A-371-Of-International US20210047663A1 (en) | 2018-04-26 | 2019-04-26 | Microbial oil/lipid and method for producing microbial oil/lipid |
US18/529,012 Division US20240117390A1 (en) | 2018-04-26 | 2023-12-05 | Microbial Oil/Lipid and Method for Producing Microbial Oil/Lipid |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2019208803A1 true WO2019208803A1 (ja) | 2019-10-31 |
Family
ID=68295580
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2019/018049 WO2019208803A1 (ja) | 2018-04-26 | 2019-04-26 | 微生物油及び微生物油の製造方法 |
Country Status (4)
Country | Link |
---|---|
US (2) | US20210047663A1 (ja) |
EP (2) | EP4219732A3 (ja) |
JP (1) | JP7394748B2 (ja) |
WO (1) | WO2019208803A1 (ja) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2022234788A1 (ja) * | 2021-05-07 | 2022-11-10 | 大学共同利用機関法人情報・システム研究機構 | 藻類の培養方法 |
WO2023145785A1 (ja) * | 2022-01-28 | 2023-08-03 | SoPros株式会社 | 血栓予防剤 |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023094996A1 (en) * | 2021-11-24 | 2023-06-01 | Dsm Ip Assets B.V. | COMPOSITIONS HAVING HIGH LEVELS OF DPA (n-3) AND METHODS FOR PRODUCING |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20090209014A1 (en) * | 2008-02-20 | 2009-08-20 | Zhanyou Chi | Heterotrophic algal high cell density production method and system |
JP2012530182A (ja) * | 2009-06-16 | 2012-11-29 | イー・アイ・デュポン・ドウ・ヌムール・アンド・カンパニー | 改良されたヤロウイア・リポリティカ(yarrowialipolytica)最適化株による高エイコサペンタエン酸油 |
JP2013055893A (ja) | 2011-09-07 | 2013-03-28 | Nippon Suisan Kaisha Ltd | 高度不飽和脂肪酸濃縮油の製造方法 |
WO2016031947A1 (ja) * | 2014-08-29 | 2016-03-03 | 国立大学法人京都大学 | エイコサペンタエン酸を高含有する脂質の生産方法 |
JP2016189787A (ja) | 2010-10-01 | 2016-11-10 | 国立大学法人九州大学 | ストラメノパイルの形質転換方法 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5130242A (en) | 1988-09-07 | 1992-07-14 | Phycotech, Inc. | Process for the heterotrophic production of microbial products with high concentrations of omega-3 highly unsaturated fatty acids |
US8399226B2 (en) * | 2009-06-16 | 2013-03-19 | E I Du Pont De Nemours And Company | High eicosapentaenoic acid oils from improved optimized strains of Yarrowia lipolytica |
FR2976951A1 (fr) * | 2011-06-21 | 2012-12-28 | Fermentalg | Nouvelles souches de microalgues du genre isochrysis pour la production d'epa et de dha en mode mixotrophe |
GB201217524D0 (en) * | 2012-10-01 | 2012-11-14 | Rothamsted Res Ltd | Recombinant organisms |
-
2019
- 2019-04-26 EP EP22214693.8A patent/EP4219732A3/en active Pending
- 2019-04-26 WO PCT/JP2019/018049 patent/WO2019208803A1/ja active Application Filing
- 2019-04-26 JP JP2020515620A patent/JP7394748B2/ja active Active
- 2019-04-26 US US17/050,133 patent/US20210047663A1/en not_active Abandoned
- 2019-04-26 EP EP19792171.1A patent/EP3786301A4/en not_active Withdrawn
-
2023
- 2023-12-05 US US18/529,012 patent/US20240117390A1/en active Pending
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20090209014A1 (en) * | 2008-02-20 | 2009-08-20 | Zhanyou Chi | Heterotrophic algal high cell density production method and system |
JP2012530182A (ja) * | 2009-06-16 | 2012-11-29 | イー・アイ・デュポン・ドウ・ヌムール・アンド・カンパニー | 改良されたヤロウイア・リポリティカ(yarrowialipolytica)最適化株による高エイコサペンタエン酸油 |
JP2016189787A (ja) | 2010-10-01 | 2016-11-10 | 国立大学法人九州大学 | ストラメノパイルの形質転換方法 |
JP2013055893A (ja) | 2011-09-07 | 2013-03-28 | Nippon Suisan Kaisha Ltd | 高度不飽和脂肪酸濃縮油の製造方法 |
WO2016031947A1 (ja) * | 2014-08-29 | 2016-03-03 | 国立大学法人京都大学 | エイコサペンタエン酸を高含有する脂質の生産方法 |
Non-Patent Citations (11)
Title |
---|
"Standard Methods for the Analysis of Fats, Oils, and Related Materials", 2013, JAPAN OIL CHEMISTS' SOCIETY (JOCS, article "2.4.2.1-2013 Fatty Acid Composition (FID constant temperature gas chromatography) and 2.4.2.2-2013 Fatty Acid Composition (FID elevated temperature gas chromatography" |
ADL, THE JOURNAL OF EUKARYOTIC MICROBIOLOGY, vol. 59, no. 5, 2012, pages 429 - 493 |
AQUAT. MICROB. ECOL., vol. 74, 2015, pages 187 - 204 |
ARMENTA, RE. ET AL.: "Single- Cell Oils as a Source of Omega-3 Fatty Acids: An Overview of Recent Advances", J. AM. OIL CHEM. SOC., vol. 90, no. 2, 2013, pages 167 - 182, XP055422807, ISSN: 0003-021X, DOI: 10.1007/s11746-012-2154-3 * |
ATHALYE, SK . ET AL.: "Use of biodiesel-derived crude glycerol for producing eicosapentaenoic acid (EPA) by the fungus Pythium irregular", J. AGRIC. FOOD CHEM., vol. 57, no. 7, 2009, pages 2739 - 2744, XP055647103, ISSN: 0021-8561, DOI: 10.1021/jf803922w * |
CHATURVEDI, R. ET AL.: "Isolation of quizalofop- resistant mutants of Nannochloropsis oculata (Eustigmatophyceae) with high eicosapentaenoic acid following N-methyl-N-nitrosoureainduced random mutagenesis", J. APPL. PHYCOL., vol. 16, no. 2, 2004, pages 135 - 144, XP055647109, ISSN: 0921-8971, DOI: 10.1023/B:JAPH.0000044826.70360.8e * |
FOLCH ET AL., J. BIOLOGICAL AND CHEMISTRY, vol. 226, 1957, pages 497 - 509 |
HOSHIDA, H. ET AL.: "Accumulation of eicosapentaenoic acid in Nannochloropsis sp. in response to elevated CO2 concentrations", J. APPL. PHYCOL., vol. 17, no. 1, 2005, pages 29 - 34, XP019247773, ISSN: 0921-8971 * |
LIU, CP. ET AL.: "Morphology and eicosapentaenoic acid production by Monodus subterraneus UTEX 151", MICRON, vol. 36, no. 6, 2005, pages 545 - 550, XP004998009, ISSN: 0968-4328, DOI: 10.1016/j.micron.2005.05.001 * |
SCOTT, SD. ET AL.: "Use of raw glycerol to produce oil rich in polyunsaturated fatty acids by a thraustochytrid", ENZYME MICROB. TECHNOL., vol. 48, no. 3, 2011, pages 267 - 272, XP028138961, ISSN: 0141-0229, DOI: 10.1016/j.enzmictec.2010.11.008 * |
VASQUEZ-SUAREZ, A. ET AL.: "Growth and biochemical composition of thalassiosira pseudonana (Thalassiosirales: Thalassiosirac eae) cultivated in semicontinuous system at different culture media and irradiances", REV. BIOL. TROP., vol. 61, no. 3, 2013, pages 1003 - 1013, XP055647105, ISSN: 0034-7744 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2022234788A1 (ja) * | 2021-05-07 | 2022-11-10 | 大学共同利用機関法人情報・システム研究機構 | 藻類の培養方法 |
WO2023145785A1 (ja) * | 2022-01-28 | 2023-08-03 | SoPros株式会社 | 血栓予防剤 |
Also Published As
Publication number | Publication date |
---|---|
US20240117390A1 (en) | 2024-04-11 |
US20210047663A1 (en) | 2021-02-18 |
EP4219732A2 (en) | 2023-08-02 |
JP7394748B2 (ja) | 2023-12-08 |
EP4219732A3 (en) | 2023-08-30 |
JPWO2019208803A1 (ja) | 2021-04-30 |
EP3786301A4 (en) | 2022-08-03 |
EP3786301A1 (en) | 2021-03-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP7134938B2 (ja) | エイコサペンタエン酸生成微生物、脂肪酸組成物、ならびにそれらの作製方法および使用 | |
US11154076B2 (en) | Eicosapentaenoic acid-producing microorganisms, fatty acid compositions, and methods of making and uses thereof | |
US10925850B2 (en) | Eicosapentaenoic acid-producing microorganisms, fatty acid compositions, and methods of making and uses thereof | |
US11525103B2 (en) | Docosahexaenoic acid-containing oil and method for producing same | |
JP2018113973A (ja) | 多価不飽和脂肪酸が高濃度化された微生物油 | |
EP1642983B1 (en) | Arachidonic acid and methods for the production and use thereof | |
US20240117390A1 (en) | Microbial Oil/Lipid and Method for Producing Microbial Oil/Lipid | |
JP2014511406A (ja) | エイコサペンタエン酸濃縮物 | |
JP2010538128A (ja) | 多価不飽和脂肪酸を含む固体脂肪組成物ならびにその使用および製造の方法 | |
US20080269329A1 (en) | Process for Production of Microbial Fat/Oil Containing Discretional Amount of Diacylglycerol and Said Fat/Oil | |
KR20150021920A (ko) | Dha의 에틸 에스테르로 미세 조류에 의해 생산되는 오일을 연속적으로 강화시키는 방법 | |
KR20220107225A (ko) | 다중불포화 지방산이 강화된 미생물 오일 조성물 | |
JPH08163990A (ja) | 油脂含有藻体およびそれから得られる油脂の製造方法 | |
KR101540741B1 (ko) | 미세조류를 이용한 도코사헥사엔산의 증진된 생산방법 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 19792171 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2020515620 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2019792171 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2019792171 Country of ref document: EP Effective date: 20201126 |